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“Grau, teurer Freund, ist alle Theorie, 
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Venous thrombosis poses a challenge to doctors of all disciplines. It is a common com-
plication among hospital inpatients and contributes to longer hospital stays, morbidity, 
and mortality. Venous thrombosis has an estimated annual incidence in western countries 
of 1-2 in 1000 persons (1;2). It is the result of the formation of a blood clot in a vein. 
This clot (the thrombus) blocks the flow of blood in the affected vein, which can cause 
pain, swelling, redness, and tenderness of the skin. Venous thrombosis can take place in 
any section of the venous system but the most common manifestation is in the veins of 
the legs. Pulmonary embolism occurs when a piece of the clot breaks off and travels to 
the lungs. Fatal pulmonary embolism occurs in 1-5% of patients with venous thrombosis 
(3). 
 Approximately 20 to 50% of patients with symptomatic venous thrombosis de-
velop the postthrombotic syndrome, which consists of chronic discomfort in the af-
fected leg or arm and is characterized by swelling and pain, and occasionally varicose 
veins and leg ulceration (4;5). 
 The treatment of choice for venous thrombosis is with oral anticoagulant ther-
apy. To maximize efficacy of treatment, and to minimize bleeding complications, fre-
quent measurement of the International Normalized Ratio (INR) is necessary. Tech-
niques for the self-management of this type of treatment have been developed and were 
found to improve quality of life of patients (6;7). 
 Venous thrombosis is a multicausal disease, caused by both genetic and environ-
mental risk factors (8). Environmental risk factors for venous thrombosis include obe-
sity, pregnancy and child-birth, the use of oral contraceptives, surgery, and prolonged 
immobility, for instance after surgery or during a long flight. A risk factor can be detected 
in about two-thirds of first-time episodes of venous thrombosis (9). A genetic abnormal-
ity predisposing to venous thrombosis by affecting blood coagulation is called thrombo-






The number of inherited disorders and risk factors that can be detected through genetic 
testing is increasing rapidly, and genetic testing is becoming a common component of 
routine medical care. Genetic testing is often applied to detect personal susceptibility to 
disease, in the belief that awareness of genetic risk will enhance informed medical deci-
sion making and have an impact on changing health behaviour (11).  
 Until recently, an abnormality affecting coagulation could only be pinpointed in a 
small minority of patients with venous thrombosis. Recently, progress has been made 
with the identification of several genetic factors that predispose to venous thrombosis 
 8 
Chapter 1 General introduction 
 
(12). Among the genetic risk factors that have been discovered so far are Factor V Lei-
den, protein C-, protein S-, and antithrombin deficiency (8). Individuals with inherited 
thrombophilia have a 16 times increased risk of venous thrombosis compared with a 
normal population (relative risk 15.7 (95% CI 9.2-26.8)) (13). Note that this risk was ob-
served in individuals who carry thrombophilic defects ánd come from pedigrees with a 
clear thrombophilic phenotype: individuals with similar defects but without a strong fam-
ily history appear to have a lower risk, indicative of multiple defects co-segregating in 
families (14,15). In addition, as the placental vessels depend on the normal balance of 
coagulation mechanisms, women with familial thrombophilia are at increased risk of fetal 
loss (16;17).  
 A debate has been going on about whether widespread thrombophilia testing is 
beneficial in terms of better prevention and management of venous thrombosis (18;19). 
Generally, it is believed such widespread testing is not justified because it is not cost-
effective (20). However, some argue that screening of patients at a very high risk of ve-
nous thrombosis is likely to be useful because it may improve clinical outcome through 
changes in the duration or intensity of therapy (21). In addition, it is believed that family 
screening of individuals with a close relative with thrombophilia may help to optimise 
prophylactic treatment of asymptomatic carriers in high-risk situations (i.e. during surgery 
or pregnancy). However, to date, there are no data supporting this view (22). Further-
more, the possible psychological consequences of genetic testing for thrombophilia have 
only received limited attention in the scientific literature. As in similar conditions such as 
hypercholesterolemia, attention should be paid to the psychological impact of testing for 
thrombophilia (23). Supporters of thrombophilia screening have stated that testing ap-
pears to reduce anxiety about the thrombotic risk (24). A statement like this should be 
taken with caution until confirmed by formal research, which is currently not available. 
 However, research has indicated that carriership of a genetic deficit may influence 
daily life, since it can cause considerable distress, especially in vulnerable individuals (25). 
Possible negative effects of a positive test result include anxiety and depression following 
the test, worry about the future and about the possibility of passing the genetic defect on 
to children. Furthermore, positive test results might cause stigmatization, problems with 
insurance, and they can interfere with medical decision making. Therefore, the psycho-
logical impact of thrombophilia screening deserves wider attention in thrombophilia re-
search and in the debate about the pros and cons of screening. 
  
 
Quality of life 
 
The World Health Organization definition of health is: ‘A state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity’(26). 
Based on this definition, quality of life (QOL) in relation to health may be defined as ‘the 
functional effect of an illness and its consequent therapy upon a patient, as perceived by 
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the patient.’ The domains that contribute to this effect are physical, psychological, and 
social functioning (26;27). 
 Whereas until about two decades ago, clinical and laboratory measurements were 
the only indicators of illness, recently, the patient’s own view on his or her health has be-
come increasingly important in clinical care and research. Nowadays, quality of life is fre-
quently used in research as an addition to more traditional clinical outcome measures, 
and large clinical trials have shown that it is responsive to important clinical changes (28).   
 Researchers have developed a large number of self-report measurements to as-
sess patients’ own views on their functioning and quality of life (29). Instruments used to 
measure quality of life can be classified into generic instruments and disease-specific in-
struments. Generic instruments allow comparisons across populations of patients with 
different diseases, whereas disease-specific instruments are sensitive to key dimensions of 
quality of life that are impaired by specific diseases. An advantage of disease-specific in-
struments is that they increase acceptability of the questionnaire to the patient by includ-
ing only relevant dimensions. A recommended research approach for assessing quality of 
life is the combination of generic and disease-specific instruments in order to combine 
the advantages of both methods (30;31). 
 Venous thrombosis is a cardiovascular disease. Quality of life in a diverse array of 
cardiovascular diseases has been the focus of many studies over the past decades (32-35). 
However, until some years ago, quality of life in patients with venous thrombosis was an 
area that did not get much attention in the literature. This is remarkable, because patients 
with venous thrombosis have to deal with an illness that is possibly fatal, might have se-
rious chronic consequences, and might return. In case of underlying thrombophilia, the 
effects can also extend to family members. Furthermore, symptomatology and treatment 
of venous thrombosis are not in any way comparable to other cardiovascular diseases, 
such as myocardial infarction or stroke. Therefore, it is highly relevant to study the qual-
ity of life of this category of patients. One woman in our studies described her first ex-
perience with venous thrombosis as follows: ‘I couldn’t do much (the first three months after 
venous thrombosis). The first month I could barely walk. I literally went from independent to infirm. 
From being a young woman with lots of plans for the future, I felt myself robbed of my health.’ 
 More recently, several researchers have focused on quality of life in this specific 
group of patients. Several reports by Kahn and colleagues have focused on quality of life 
after venous thrombosis, especially in the presence of the postthrombotic syndrome, and 
have found that at first, QOL is impaired in patients with venous thrombosis, but usually 
improves in the first four months after venous thrombosis. However, in about one third 
of patients, QOL remains poorer than population norms, especially in patients that suffer 
from the postthrombotic syndrome (36-38). Similar results were found by Locadia and 
colleagues, who assessed the impact of the duration of anticoagulant treatment after ve-
nous thrombosis on quality of life (39). Apart from the finding that quality of life in pa-
tients with venous thrombosis improved over time, this study also showed that quality of 
life was not related to treatment duration. 
 10




Quality of life in patients with a chronic illness has been studied extensively, and research 
has shown that the level of disability as experienced by the patient can not be explained 
by mere biomedical variables. Therefore, research on quality of life has focused on other 
factors that influence the perceived impact of the illness. The patient’s own perceptions 
of an illness were found to play an important role in explaining quality of life. Leventhal’s 
Common-Sense Model (CSM) of health and illness behaviour (see Figure 1) is a model 
that describes a system with two parallel pathways that interact when a patient adapts to 
an illness or health threat (40;41). Components of the first pathway are the cognitive rep-
resentations of an illness. Those representations (also called illness perceptions) include 
five key attributes: the label and symptoms that patients associate with their illness (iden-
tity), and their beliefs about the etiology (cause), the outcome (consequences), the dura-
tion (timeline) and the controllability (cure/control) of the illness (40;42). The second 
pathway involves the emotional response to an illness. Together, these illness perceptions 
can lead to a diverse array of health outcomes, possibly through coping behaviours. 
  
 
Figure 1. Common-Sense Model of Illness representations  
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Several assessment tools of illness perceptions have been developed over the years, in-
cluding interviews and a number of questionnaires (43;44). The Illness Perceptions Ques-
tionnaire (IPQ) and its revised version, the Illness Perceptions Questionnaire-Revised 
(IPQ-R) are the most widely used examples (45;46).  
 Quality of life factors represent important outcome components of the Com-
mon-Sense Model. The influence of illness perceptions on the quality of life of patients 
with a chronic disease has been investigated in a number of studies. These studies have 
provided support for the hypothesis that a strong illness identity (the attribution of many 
symptoms to an illness), as well as a belief in a long duration and serious consequences of 
an illness have a negative effect on the well-being of patients (47;48).  
 Illness perceptions in patients with cardiovascular diseases have been studied to 
some extent (49-51), but to date, no studies have assessed the illness perceptions and 
their influence on outcome in patients with venous thrombosis. 
 
 
Psychological consequences of genetic testing 
 
Informing people of their genetic susceptibility to a disease may motivate them to change 
their behaviour to reduce their risk (52;53). However, carriership of a genetic deficit may 
also influence daily life, since it may cause considerable distress, especially in vulnerable 
individuals (25). Possible negative effects of a positive test result include anxiety and de-
pression following the test, worry about the future and about the possibility of passing 
the genetic defect on to children, especially in highly anxious individuals (54). Further-
more, positive test results might cause stigmatization, problems with insurance, and they 
may interfere with medical decision making. Some even argue that family and kinship 
become medicalized as a result of the current emphasis on medical genetics (55). 
 As mentioned above, the possible psychological consequences of genetic testing 
for thrombophilia have not been studied before. In addition to the general psychological 
distress following a genetic test, it is important to study perceived risk about developing 
venous thrombosis in thrombophilic individuals. Perceived risk of disease is the expec-
tancy of an individual of developing a specific disease at some point in his or her life. 
Perceived risk has been identified as a motivator for health behaviour in several studies. 
In the area of cancer screening, risk perceptions have been found to be often inaccurate 
perceptions of the actual risk of cancer (56). Moreover, risk perceptions have been found 
to be positively associated with screening intentions, and preventive behaviour such as 
breast self-examinations (57;58). Inaccurate perceptions of risk tend to persist even after 
genetic counselling (59). These inaccurate perceptions of disease risk could have a nega-
tive effect on well-being and preventive behaviour. A growing body of research indicates 
that disease-related worry also plays a motivational role in promoting health behaviour, 
with an effect that is sometimes even stronger than the effect of risk perception (60;61). 
 Improved understanding of how individuals estimate their personal disease risk 
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and what factors influence their disease related worry, is critical in understanding the rela-
tionship between risk perception, worry, and health behaviour. Perceptions of health 
risks such as a genetic risk factor predisposing to an illness are based on perceptions of 
the target illness, and so the construction of risk perception must be consistent with the 
theoretical understanding of illness representations. In this light, the Common-Sense 
Model of illness representation can be useful in understanding risk perceptions and worry 
about disease in patients at a genetic risk for a disease (62-66). Although the CSM has 
primarily been applied to understanding outcome in patients who are physically ill, it is 
likely that illness perceptions are also important predictors of the response to health 
threats in healthy individuals, such as a genetic predisposition to an illness (67). In fami-
lies with a history of venous thrombosis, it is likely that genetically predisposed but as-
ymptomatic family members have witnessed episodes of venous thrombosis in their 
close relatives. This experience, together with the information patients have received 
from medical caregivers and have gathered themselves (e.g. through the internet), might 
have generated illness perceptions about thrombosis, which in turn can guide the reac-
tion to this health treat.   
 
 
Aims of the studies described in this thesis 
 
Since 1985 a large North-American family (n~800) with protein C deficiency due to the 
3363C mutation has been studied (IPCI: International Protein C Investigation) (68). It is 
likely that this mutation was introduced in North America by a couple of French settlers 
who established themselves in 1669 near Québec City (69). A family of this size is ideal 
to study the psychological aspects of genetic testing for thrombophilia. Collaboration 
between the Department of Clinical Epidemiology (LUMC), the Unit of Psychology 
(LUMC) and the Department of Pathology of the University of Vermont (VT, USA) was 
established. This collaboration resulted in several studies on quality of life in patients 
with venous thrombosis and the psychological impact of thrombophilia testing, of which 
the results are described in this thesis.  
 The first aim of this thesis was to study the quality of life of patients with venous 
thrombosis and to examine the role of illness perceptions in explaining the quality of life 
of these patients. The second aim of this study was to study the psychological conse-
quences of genetic testing for thrombophilia, using the Common-Sense Model as a theo-
retical framework. As mentioned above, the Common-Sense Model can prove to be a 
useful model in explaining a diverse array of outcomes in individuals that are at risk of a 
disease. With our research we hope to contribute to the knowledge of how we can apply 
the Common-Sense Model to an ‘at risk’ population and how we can place perceptions 
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Outline of this thesis 
 
The thesis is divided into two parts. Part 1, consisting of chapters 2, 3, and 4, focuses on 
the first aim of the thesis and describes the quality of life and illness perceptions of pa-
tients with venous thrombosis.  
 Chapter 2 presents an overview of the existing literature about quality of life in 
chronic venous diseases.  
 Chapter 3 presents the results of a study that was conducted at the thrombosis 
clinic of the University of Vermont in Burlington (VT, USA). The chapter focuses on the 
measurement of quality of life in patients with a history of venous thrombosis. The aim 
of this study was to examine the impact of venous thrombosis on quality of life in a well-
defined population of patients with venous thrombosis by using both a generic and a 
newly developed disease-specific measure and to study the relationship between quality 
of life, the presence of symptoms, and the presence of the postthrombotic syndrome.  
 Chapter 4 is based on the same study as chapter 3. This chapter describes illness 
perceptions in patients with venous thrombosis, and examines their role in the quality of 
life of these patients. 
 The second part of this thesis deals with the second aim. This part consists of 
chapters 5 and 6, and focuses on the psychological consequences of genetic testing for 
thrombophilia.  
 Chapter 5 describes the results of a study in a large family with a high incidence 
of heritable protein C deficiency and venous thrombosis (IPCI: International Protein C 
Investigation). The aim of this chapter was to explore the attitudes of protein C deficient 
individuals about genetic testing and to establish the correlates of risk perception, trait 
anxiety, and thrombosis-related worry in these attitudes. 
 Chapter 6 focuses on the illness perceptions about venous thrombosis in patients 
with a genetic predisposition to the disease. Participants in this study were adult trombo-
philic individuals who were enrolled in the European Cohort on Thrombophilia 
(EPCOT) study in the Netherlands. The aim of this study was to use the Common-Sense 
Model as a theoretical framework to predict risk perception and worry about venous 
thrombosis. 
 The thesis concludes with a general discussion. The major results of the studies 
described in this thesis, their strengths and limitations, and suggestions for further re-
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Quality of life (QOL) can be defined as 'the functional effect of an illness and its conse-
quent therapy upon a patient, as perceived by the patient.' Studies on the impact of 
chronic venous disease on quality of life are scarce compared to quality of life research in 
other diseases.  
The purpose of this paper was to describe instruments that assess quality of life in 
patients with chronic venous disease and to review the literature on this topic. A com-
puter search of the MedLine database was performed to identify papers, and the bibliog-
raphies of relevant articles were reviewed to obtain additional papers. Papers were in-
cluded if they described the development or use of a quality of life instrument for pa-
tients with chronic venous disease. 
A total of 25 papers were identified that fit the inclusion criteria. The studies de-
scribed in the papers used six different generic instruments and ten disease specific in-
struments. Quality of life in chronic venous disease was assessed in 12 studies. Six stud-
ies compared different types of treatment for chronic venous disease where QOL was an 
outcome measure. 
Despite the wide variety of measures used, results indicate that quality of life of pa-
tients with chronic venous disease is affected in the physical domain mostly with regard 
to pain, physical functioning and mobility, and that they suffer from negative emotional 
reactions and social isolation. We feel that QOL should be a standard measure in future 
studies in patients with chronic venous disease, preferably with a combination of generic 





Quality of life (QOL) can be defined as 'the functional effect of an illness and its conse-
quent therapy upon a patient, as perceived by the patient’ (1). These functional effects 
are usually operationalized as (limitations in) physical, psychological and social function-
ing. Quality of life is increasingly seen as an important outcome measure in diagnostic 
and treatment studies because of the publication of several large clinical trials showing 
that quality of life as an outcome measure is responsive to important clinical changes (2). 
In addition to relieving clinical symptoms and prolonging survival, a primary objective of 
any health care intervention should be the enhancement of the well-being of the patient 
(3).  
Chronic venous disease may affect several aspects of quality of life. It also requires 
medical care. Treatment often involves hospital admission and invariably treatment with 
anticoagulants, which may also have an impact on quality of life. 
There have been numerous studies on the etiology, diagnosis, and management of 
chronic venous disease and about the cost-effectiveness of treatment, but few have ex-
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A total of 25 papers fitted the inclusion criteria of describing the development, validation 
or use of a quality of life measure in patients with chronic venous disease. Twenty-three 
papers were in the English language, two papers were written in German. Table 1 pre-
sents a summary of the 25 papers classified according to the sample that was investi-
gated. The first part of this section will describe two categories of instruments for assess-
ing QOL in chronic venous disease: generic instruments and disease-specific instru-
ments. In the next part of this section the studies assessing QOL in chronic venous dis-






ation, were included. 
A computer search of the MedLine database from 1966 to February 2003 was performed 
to identify relevant papers. The following entries were used: (venous thrombosis) and 
(quality of life). In addition, we reviewed the bibliographies of relevant articles to obtain 
additional papers. Papers were selected if they met the following inclusion criteria: they 
were written in the English, French or German language and they had to describe the 
development or use of a quality of life instrument in venous thrombosis or treatment of 
venous thrombosis. Because the search specific for ‘venous thrombosis’ yielded only few 





The purpose of this paper is to describe instruments that have been used to assess 
quality of life in patients with chronic venous disease, and to review the literature regard-
ing the impact of chronic venous disease on quality of life. 
Instruments used to measure quality of life can be classified into generic instru-
ments and disease-specific instruments. Generic instruments allow comparison across 
populations of patients with different diseases, whereas disease specific instruments are 
sensitive to key dimensions of quality of life that are impaired by specific diseases. There-
fore, combining generic and disease specific instruments is a preferred strategy in exam-
ining quality of life (4).
amined the impact of chronic venous disease on quality of life. Studies on chronic ve-
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Legend Table 1 
CIVIQ: Chronic Lower Limb Venous Insufficiency Questionnaire 
CVI: Chronic venous insufficiency  
DVT : Deep vein thrombosis 
EQ: Euro-QOL 
FAI: Frenchay Activities Index 
PTS: Postthrombotic syndrome 
QOL: Quality of life 
SF-36: Short Form-36 
SF-20: Short Form-20 
SF-12: Short Form-12  
SF-MPQ: McGill Short Form Pain Questionnaire  
VAS: Visual Analogue Scale 
 
 
Review of available instruments  
The generic and disease specific instruments used in the reviewed studies will be de-
scribed and their reliability and validity will be discussed. An instrument is reliable when 
it consistently produces the same results when applied to the same subjects when there is 
no evidence of change (5). One way to assess reliability is to determine the internal-
consistency reliability coefficient, which reflects the degree of relatedness between the 
individual items that make up a scale (6). The items should all measure the same concept, 
and therefore should be correlated with each other. A measure of overall internal-
consistency reliability is Cronbach's alpha (7). Cronbach’s alpha is a function of the num-
ber of test items and the average inter-correlation among the items. Alpha coefficients 
ranges in value from 0 to 1.  In general, for comparing groups, a reliability coefficient or 
Cronbach's alpha higher than 0.70 is acceptable (8). 
Validity is concerned with whether the indicator actually measures the underlying 
attribute or not. Validity of a quality of life measure is usually determined by examining 
correlations between conceptually related measures and by studying associations between 
the measure and various clinical characteristics (6).
 
Generic QOL instruments 
 
The generic instruments used in the reviewed studies are depicted in Table 2. The most 
widely used generic instrument to measure quality of life is the Short Form 36 (SF-36) 
(9).The SF-36 consists of 36 items spread over 8 dimensions, plus a single item giving 
information on change in health over the past year.  
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Table 2: Generic QOL instruments  
 
First author & Year Instrument Measured dimensions of QOL 
Holbrook, 1983 (25) Frenchay Activities Index 
(FAI) 
Physical: domestic chores, lei-
sure/work, outdoor activities 
Hunt, 1986 (20) Nottingham Health Profile 
(NHP) 
Physical: physical mobility, pain 
Psychological: emotional reaction  
Social: social isolation  
Other: sleep, energy 
Kellner, 1973 (26) Symptom Rating Test (SRT) Psychological: depression, anxiety, cog-
nitive function, hostility 
Melzack, 1987 (24) McGill Short Form Pain 
Questionnaire (SF-MPQ) 
Physical: pain 
The EuroQol group, 
1990 (23) 
EurQol (EQ) Physical: mobility, self care, usual ac-
tivities, pain 
Psychological: anxiety 
Ware, 1993 (9) Short Form 36 (SF-36)  Physical: physical functioning, role 
limitations physical, bodily pain 
Psychological: role limitations emo-
tional, general mental health, en-
ergy/vitality 
Social: social functioning  
Other: general health perceptions 
 
Legend: for abbreviations, see Table 1 
A major advantage of the SF-36 is its extensive application in several disease conditions 
and extensive validation in several populations. A paper about quality of life measure-
ment found that the SF-36 was the most widely evaluated measure, over 10% of the 
3921 reviewed reports used it (10). The original version of the SF-36 was used in six of 
the reviewed studies (11-16), two studies used modified versions, the SF-20 (17) and the 
SF-12 (18), and another study used items of the SF-36 in a standardized interview (19).  
The Nottingham Health Profile is another generic QOL instrument (20). It in-
cludes 38 items covering six domains. It has been used extensively in outcome studies in 
several clinical areas such as cardiovascular and rheumatological diseases. The NHP was 
used in two studies on patients with leg ulceration (21;22).
The EuroQol (EQ) (23), McGill Short Form Pain Questionnaire (SF-MPQ) (24), 
and Frenchay Activities Index (FAI) (25) are all generic QOL measures and were evalu-
ated together with the SF-36 for use in patients with venous leg ulcers in a study by Wal-
ters et al. (13). The EQ consists of 5 dimensions, which measure physical and psycho-
logical status. The SF-MPQ is a quantitative measure of pain and the FAI measures ac-
tivities that reflect level of independence.  
The Symptom Rating Test (SRT) measures psychological state, such as depression 
and anxiety, and was developed as an outcome measure for drug trials (26). Franks and 
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colleagues used it as a quality of life instrument in two studies with patients with venous 
disease and leg ulcers (27;28).  
The answer to the question: ‘which questionnaire should we use?’ depends entirely 
on the research question under study. There is no ‘gold standard’ for assessing quality of 
life and therefore no simple answer (29). However, we feel that for the purpose of assess-
ing quality of life in patients with chronic venous disease, an instrument that measures 
quality of life on the of domains of physical, psychological and social functioning is most 
appropriate as patients seem to have an impairment in all three domains. This means that 
the NHP and SF-36 are both good choices. 
 
 
Disease specific instruments 
 
Ten disease specific questionnaires were found that have been designed to measure 
QOL in specific groups of patients with chronic venous disease. Table 3 lists the QOL 
dimensions assessed by the various questionnaires. This section will discuss the instru-
ments classified by the diagnostic category of patients they were developed for.  
 
Instruments for venous disease 
 
Augustin et al. describe the development and validation of a 83-item German disease-
specific questionnaire on QOL in patients with chronic venous insufficiency (CVI): The 
Freiburger Questionnaire of QOL in venous diseases (FLQA) (30). Generally high inter-
nal consistency (α >0.70 in all subscales) and high correlations with the NHP provide 
evidence for the reliability and validity of the scale.  
Franks et al. (28) designed a 36-item questionnaire to determine risk factors, quality 
of life, and use of health resources in patients with venous disease. This instrument con-
tained the Symptom Rating Test and questions about symptoms and daily activities. Reli-
ability and validity of this instrument have not been evaluated.  
Another questionnaire that is only available in German was developed by Klyscz et 
al. (31) for measuring QOL in patients with CVI. This questionnaire meets the require-
ments of psychometric standards (i.e. adequate reliability and validity) and has proven its 
use in clinical settings by distinguishing between Stage I/II and Stage III CVI patients 
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Table 3: Disease specific QOL instruments 
 
First author & 
Year 
Instrument & Population Dimensions 
 Venous disease  
Augustin, 1997 
(30) 
The Freiburger Questionnaire of 
QOL in venous diseases (FLQA) 
(German) 
Physical: physical complaints, everyday life 
Psychological: emotional status 
Social: social life 
Other: therapy, satisfaction, occupation 
Franks, 1992 (27) 
 
 
Health questionnaire for venous dis-
ease 
 
Physical: symptoms, daily activities 
Psychological: Symptom rating test 
 
Klyscz, 1998 (31) The Tübingen questionnaire for 
chronic venous insufficiency (TLQ-
CVI) (German) 
Physical: physical condition, functional status 
Psychological: psychological wellbeing 
Social: social repercussions 
Other: general health and QOL 
Lamping, 1998  
(33;34) 
VEINES-QOL 
(for chronic vascular disorders of the 
leg) 
Physical: symptoms, limitations in daily activities 
Psychological: psychological impact 
Other: changes in the past year, time of day of highest 
symptom severity 
Launois, 1996 (32) CIVIQ 
(for chronic venous insufficiency) 
Physical: pain, physical functioning 
Psychological: psychological functioning 
Social: social functioning 
 Venous thrombosis  
Mathias, 1999 (35) Health-related quality of life question-
naire for deep vein thrombosis 
Physical: physical health (SF-12) 
Psychological: mental health (SF-12) 
Other: energy/vitality, health distress, disease interfer-
ence, Health Utilities Index: emotion, cognition, self-
care, pain, vision, hearing, speech, ambulation, dexterity 
 Venous leg ulceration  
Franks, 1994 (21) 
 
Health questionnaire for leg ulcers Physical: symptoms, daily activities 
Psychological: Symptom rating test 
 
Hyland, 1986 (36) Self-report QOL questionnaire for 
patients with leg ulcers 
Physical: functional limitations 
Psychological: dysphoric mood 
Other: treatment 
Smith, 2000 (12) Charing Cross venous ulcer question-
naire 
Physical: domestic activities 
Psychological: emotional status 
Social: social functioning 
Other: cosmetic appearance 
 Varicose veins  
Garratt, 1993 (14) Clinical varicose veins questionnaire Physical: symptoms, pain, interference with daily activi-
ties and work 
Other: treatment, concern about appearance 
 
Legend: for abbreviations, see Table 1 
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Launois et al. constructed the 20-item Chronic Lower Limb Venous Insufficiency 
Questionnaire (CIVIQ) (32). The CIVIQ was validated in a large study sample of 2001 
patients and each dimension showed to have good internal consistency and reproducibil-
ity.  
The VEINES-QOL, developed by Lamping et al., is a 26-item questionnaire de-
signed for use in patients with chronic vascular disorders of the leg. Four language ver-
sions (English, French, French Canadian and Italian) have been developed and each ver-
sion has been evaluated and the results confirmed its reliability and validity (15;33;34).  
As previously stated, the decision of which questionnaire to use depends on the research 
questions of a study. The CIVIQ and the VEINES-QOL may be good choices for as-
sessing QOL in English speaking people with venous diseases, because they are short, 
well validated and cover most important issues. For German speaking patients, the 
FLQA would be an appropriate choice.  
 
Instruments for venous thrombosis 
 
Only one questionnaire was specifically designed for use in patients with venous throm-
bosis. Mathias et al. developed a health-related quality of life measure for patients with 
deep vein thrombosis (35). The questionnaire items were derived from the Health Utili-
ties Index and the SF-12. New items were developed that were specific for DVT. The 
internal consistency was good, with Cronbach’s α values ranging form 0.69 to 0.95, but 
not all items showed good variability. 
 
Instruments for venous leg ulceration 
 
For use in patients with leg ulcers, Franks et al. adapted their questionnaire to fit the spe-
cific problems of patients with leg ulcers, such as pain and interference with daily activi-
ties (27). The validity and reliability of this instrument have not been evaluated. 
Two QOL questionnaires have been specifically developed for patients with leg ulcers. 
The questionnaire by Hyland et al. consists of the following sections: issues central to the 
experience of the ulcer, and a list of 29 QOL items (36). This questionnaire has not been 
formally evaluated regarding validity, but there was some evidence for reliability based on 
inter-item correlations in a study with a sample of 50 patients. 
Another 32-item QOL questionnaire for patients with venous ulcers was devel-
oped by Smith et al. (12) The questionnaire showed good internal consistency (α = 0.93) 
and test-retest analysis (r = 0.84). Validity was demonstrated by high correlations of the 
questionnaire with all eight domains of the SF-36.  
The questionnaire by Smith et al. seems to be the best choice for evaluating QOL 
in patients with leg ulcers because it covers all aspects of quality of life and has good va-
lidity and internal consistency. 
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Instruments for varicose veins 
 
A 15-item questionnaire for patients with varicose veins was developed by Garratt et al. 
(14). It has shown a high correlation with the SF-36 and a good internal consistency, and 
therefore there is some evidence of its reliability and validity. 
 
 
Review of clinical study results 
 
In this section the studies that conducted quality of life measurement in patients with 
chronic venous disease and related conditions are reviewed. The studies are presented 
according to the diagnostic category of patients under investigation. 
 
Quality of life in patients with venous disease 
 
In a study of 114 patients with venous disease matched with 114 healthy control sub-
jects, quality of life was measured with self-reported symptoms and the Symptom Rating 
Test (28). More cases than controls reported a history of symptoms of venous disease 
like leg swelling, cramps, itching, restlessness and pain. There were no differences be-
tween the two groups in the areas of the SRT, such as depression, anxiety or hostility.  
 
Quality of life in patients with venous thrombosis 
 
Four studies examined QOL in patients with venous thrombosis; three studies used a 
combination of disease-specific and generic measures (11;19;35), and one study used 
only a disease-specific measure (37).  
A longitudinal study of venous disorders followed 124 patients with deep vein 
thrombosis 6 to 8 years after thrombosis was diagnosed (19). A 75 item interview was 
applied, containing items about symptoms and treatment and 19 items from the SF-36. 
At follow up (6-8 years after diagnosis) 52 patients were interviewed of whom 42% still 
reported pain, swelling, or discoloration of the leg. The symptoms were rated as mildly 
or moderately severe. On the SF-36, symptomatic patients had lower perceptions of their 
health, lower levels of physical functioning and more severe role limitations due to 
physical health compared to non-symptomatic patients. 
A recent study by Kahn and colleagues assessed 41 patients with previous deep 
vein thrombosis, of whom 19 had postthrombotic syndrome (PTS) (11). They measured 
quality of life with the SF-36 and the VEINES-QOL. It was found that postthrombotic 
syndrome had a significant impact on quality of life measured by the disease-specific 
VEINES-QOL. No differences between patients with and without PTS in quality of life 
measured by the SF-36 were observed. 
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Mathias and colleagues studied 111 patients with deep vein thrombosis who had 
received treatment with urokinase or standard heparin for DVT at least 6 months prior 
to identification (35). Three groups were distinguished; those with no symptoms, moder-
ate symptoms, and severe symptoms, as determined by a physician at baseline measure-
ment. The group with no symptoms reported better functioning on nearly every scale of 
the questionnaire compared to the group with moderate symptoms. The group with 
moderate symptoms reported better functioning compared to the group with severe 
symptoms. The only significant differences between those two groups were found on 
stigma and overall symptoms, borderline differences were found on health distress and 
physical functioning. 
Ziegler et al. investigated 161 patients who had been treated for deep vein throm-
bosis (37). Of these patients, 82% suffered from post-thrombotic syndrome. A modified 
version of the CIVIQ with questions about pain was completed by 56 patients. No limi-
tation was reported by 29% of patients, 25% were only mildly impaired in their quality of 
life and 46% of patients evaluated their restriction in QOL as moderate. Estimated im-
pairment of quality of life was associated with the clinical severity of the postthrombotic 
syndrome. Separate analyses on the four dimensions of the CIVIQ were not reported. 
 
Quality of life in patients with venous leg ulceration 
 
Five studies assessed QOL in patients with leg ulcers; disease-specific measures were 
used in four studies (27;36;38;39), and one study used a generic QOL measure (22).  
Charles interviewed four patients with leg ulcers (38). Open-ended interviews were 
used. The interviews demonstrated that patients with chronic leg ulcers suffered negative 
effects in the physical, psychological and social areas of their lives. 
Franks et al. interviewed 185 leg ulcer patients who visited a community leg ulcer 
clinic (27). The patients were interviewed at their first visit to the clinic and after 12 
weeks of treatment. Symptom Rating Test scores at 12 weeks showed reductions in anxi-
ety, depression, hostility and changes in cognition compared with baseline scores. Inter-
ference with daily activities also decreased, but the effect on 'general health' did not.  
Fifty leg ulcer patients completed a QOL questionnaire in a study by Hyland et al. 
(36). Approximately one-third of patients in this sample reported substantial functional 
limitations and negative emotions because of their ulcer. A remarkable result was that 
self-care behavior was unrelated to level of pain or quality of life. 
In the study by Lindholm and colleagues, the NHP was used to assess quality of 
life in 125 chronic leg ulcer patients (22). Compared to population norms, leg ulcer pa-
tients showed poorer QOL especially with regard to pain, social isolation, emotional re-
actions and physical mobility. Men with leg ulcers showed poorer QOL than women 
with leg ulcers. 
Phillips et al. conducted standardized interviews with 73 patients with chronic leg 
ulcers (39). Most patients suffered from moderate to severe symptoms, especially pain. 
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81% believed that the ulcer adversely affected their mobility. For the working patients, 
leg ulcers were correlated with time lost from work, job loss and adverse effects on fi-
nances. Of all patients, 68% reported that the ulcer had a negative emotional impact on 
their lives.  
 
Quality of life in patients with varicose veins 
 
Our search yielded two descriptive studies of quality of life in patients with varicose 
veins, both of which used a combination of disease-specific and generic measures.  
A questionnaire survey of 281 varicose veins patients and 542 control subjects was 
conducted by Garratt et al. (14). The perceived health of patients with varicose veins 
measured on the SF-36 was lower than that of the control sample.  
A cross-sectional population based study assessed 1054 patients with varicose veins 
and 259 control subjects (15). Patients with varicose veins had lower scores on the SF-36 
physical and mental health dimensions compared to population norms. The scores on 
the physical dimension decreased according to the increasing severity of the concomitant 
disease, with lowest scores found in patients with varicose veins and an active ulcer. 
However, no differences were found between patients with varicose veins alone and 
control subjects. Thus, results indicate that impairment of QOL in patients with varicose 
veins is associated with underlying venous disease, rather than with varicose veins alone. 
 
Quality of life in patients with different types of treatment 
 
Six studies examined the effect of different kinds of treatment on quality of life in pa-
tients with venous thrombosis; two studies used both disease specific and generic in-
struments (17;18), one study applied only a generic measure (16), and the other three 
studies used only a disease specific instrument (40-42). One study examined the effect of 
surgery compared to standard anticoagulation as treatment for DVT and found that pa-
tients treated with surgery had better quality of life after treatment, reported less symp-
toms and had better functioning (41). This study was not randomized so the results 
should be interpreted with some caution. Comerota et al. found that patients with ilio-
femoral DVT treated with catheter-directed thrombolysis had better functioning and 
well-being, compared with patients treated with anticoagulation alone (18). This study 
was not randomized either, so future randomized trials to confirm the results of the two 
studies mentioned above are needed.  
Frank et al. (40), Koopman et al. (17), and O’Brien et al. (16) compared the effect 
of outpatient treatment with hospital treatment of acute DVT on QOL. Koopman et al. 
studied 198 patients who were treated with standard heparin in the hospital and 202 pa-
tients who received low-molecular weight heparin at home (17). Quality of life improved 
in both groups after treatment, but physical activity and social functioning were better in 
the low-molecular weight heparin group. Frank et al. on the other hand, found that in 
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their group of patients with in-hospital treatment (N = 13) well-being was higher than in 
the outpatients (N = 14) (40). O'Brien assessed quality of life in 151 patients receiving 
standard heparin and 149 patients receiving low-molecular weight heparin and found 
significant results only in the domain of social functioning, which was better in patients 
receiving low-molecular weight heparin (16). This result is consistent with that of Koop-
man et al.(17)   
Kulinna et al. examined the effect of self-monitoring the INR in 100 patients on 
anticoagulant medication and found that this treatment regime improved quality of life, 






A number of findings stand out when reviewing the topic of quality of life in patients 
with chronic venous disease. First, the number of empirical studies is low compared to 
the number of studies on quality of life in patients with other diseases: a review of the 
literature about QOL in patients with lung cancer between 1970 and 1995 revealed 151 
papers (43), whereas our search only yielded 25 papers. Secondly, the use of a wide range 
of instruments in the reviewed studies indicates a lack of consensus concerning the best 
way to measure QOL in the area of chronic venous disease. Thirdly, despite the short 
tradition in assessing QOL in chronic venous disease, it appears that the studies re-
viewed here have identified some major areas of QOL affected by chronic venous dis-
ease. In summary, patients with venous thrombosis report pain and impairment of their 
physical functioning. They also report low health perceptions and high health distress. 
Impairment of QOL appears to be related to symptom severity and the presence of the 
postthrombotic syndrome. Patients with venous leg ulceration report impairment of 
their physical functioning and mobility and suffer from negative emotions and social iso-
lation. Patients with varicose veins reported a lower health perception than a control 
sample but real impairment of QOL in patients with varicose veins seems to be associ-
ated with underlying venous disease. 
Improvement of QOL after treatment in patients receiving low-molecular weight 
heparin appears to be similar to the QOL improvement of patients receiving in-patient 
treatment with standard heparin in the hospital. 
The majority of studies applied generic quality of life measures, in particular the 
Short-Form 36, which provides the possibility to characterize patients with venous 
thrombotic disease in comparison with other clinical samples and the healthy population. 
However, in the study by Kahn et al. (11), the SF-36 could not detect any differences 
between patients with and without PTS whereas the VEINES-QOL did detect some dif-
ferences. This might indicate that a generic measure might not be sensitive to any spe-
cific effects of PTS. Of the disease specific measures used in the reviewed studies, only 
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few have been adequately validated in large groups of patients. In most of these instru-
ments the social dimension has been neglected or only partially captured. Because we 
feel that this is an important issue, we recommend the use of an instrument that assesses 
this domain as well and is well validated, such as the CIVIQ (32). 
A potential limitation of this review is that we might have missed some publica-
tions due to our search strategy. However, to our knowledge, we have been thorough in 
our search for papers. 
A potential limitation of the reviewed studies is that most of the reported studies 
are questionnaire-surveys. There are recognized limitations in questionnaire studies in-
cluding patients with low literacy skills or poor eyesight who might not be able to com-
plete them, and that long and demanding questionnaires might reduce compliance. In 
addition, most of the used questionnaires have not been formally evaluated for reliability 
and validity. Further, responses on questionnaires that were administered retrospectively 
could suffer from a response bias. 
Given the impact of chronic venous disease on quality of life as described in this 
review, we feel that QOL should be a standard measure in future studies on clinical work 
in patients with chronic venous disease. A preferred approach in these studies would be 
a combination of generic and disease specific measures to allow the results to be com-
pared to other samples and to detect key dimensions of quality of life impaired by 
chronic venous disease. The European Organization for Research and Treatment of 
Cancer (EORTC) took the initiative to develop a quality of life instrument for patients 
with cancer, the QLQ-C30, which is validated in 43 languages and used in more than 
3000 studies worldwide. It would be an exciting idea for the future if a similar disease 
specific instrument was developed for patients with venous thrombotic disease and ap-
plied as a standard measure in all clinical studies. Until that day, a combination of well-
validated generic and disease specific measures, for instance the SF-36 and VEINES-
QOL or CIVIQ, would be the preferred approach.  
Second, there should be a focus on longitudinal research about the long-term ef-
fect of chronic venous disease on quality of life and on the effect of chronic venous dis-
ease on the well being of the partners of the affected individual. In clinical work on pa-
tients who use anticoagulation, there should be more attention to the negative effects of 
this treatment on the quality of life of patients, for instance, the fear of hemorrhage and 
the burden of regular hospital visits.  Eventually, intervention studies to improve the 
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Quality of life (QOL) is increasingly seen as an important outcome in clinical care. Etiol-
ogy, diagnosis, and management of venous thrombosis have been studied extensively, 
but only few studies have examined the impact of venous thrombosis on quality of life. 
The purpose of this study was to examine the impact of venous thrombosis on quality of 
life in a well-defined population of patients with venous thrombosis, by using both a ge-
neric and a disease-specific quality of life measure. A total of 45 patients from the 
thrombosis clinic of the University of Vermont in Burlington, VT, returned a mailed 
questionnaire including the Short-Form 36 (SF-36) and a disease-specific quality of life 
questionnaire (VT-QOL) about the problems faced by patients with venous thrombosis. 
The sample consisted of 13 men (28.9%) and 32 women (71.1%). The mean age 
was 44.1 years, with a range from 21 to 80 years. Compared with population norms of a 
general U.S. population that were adjusted for age and sex (N= 2,463), venous thrombo-
sis patients scored significantly lower (p < 0.05) on all subscales of the SF-36. Patients 
with the postthrombotic syndrome appeared to have more impairment in their quality of 
life as measured by both the SF-36 and the disease-specific questionnaire. All correlations 
between the SF-36 subscales and the subscales of the VT-QOL were significant, most of 
them on a p < 0.01 level. Given the impact of venous thrombosis and the postthrom-
botic syndrome on quality of life, assessment of QOL should be included in future stud-





Whereas until about two decades ago, clinical and laboratory measurements were the 
only indicators of illness, recently, the patient’s own view on his or her health has be-
come increasingly important in clinical care and research. Researchers have developed a 
great number of self-report measurements to assess patients’ own views on their func-
tioning and quality of life (1). Several large clinical trials have shown that quality of life as 
an outcome measure is responsive to important clinical changes and therefore it is in-
creasingly seen as an important outcome measure in diagnostic and treatment studies (2).  
The World Health Organization definition of health is: ‘A state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity’ (3). 
Based on this definition, quality of life in relation to health, may be defined as ‘the func-
tional effect of an illness and its consequent therapy upon a patient, as perceived by the 
patient.’ The domains that contribute to this effect are physical, psychological, and social 
functioning (3;4). 
 The annual incidence of diagnosed venous thrombosis in western countries is 1 
per 1000 persons (5;6). In about 20% of patients, venous thrombosis extends proximally, 
and of those patients, 1-5% develop fatal pulmonary embolism (7). The postthrombotic 
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syndrome (PTS) is a chronic condition consisting of leg pain, edema, venous ectasia, skin 
induration and ulceration and is estimated to occur in up to 50% of patients after an epi-
sode of venous thrombosis (8;9). 
 Etiology, diagnosis, and management of venous thrombosis have been studied 
extensively but only a few studies have examined the impact of venous thrombosis on 
quality of life. Assessment of quality of life in conditions like venous thrombosis may 
provide important information on the burden of an illness that is not normally captured 
by traditional measures of morbidity (10).
A review on the subject of quality of life in patients with chronic venous diseases 
identified a total of 25 papers (11), of which 4 dealt with the assessment of QOL in ve-
nous thrombosis (12-15). These studies indicate that patients with venous thrombosis 
report pain and impairment of their physical functioning. They also found that patients 
have low perceptions of their general health and high health distress. Impairment of 
QOL appears to be related to symptom severity and the presence of the postthrombotic 
syndrome. 
 Instruments used to measure quality of life can be classified into generic instru-
ments and disease-specific instruments. Generic instruments allow comparison across 
populations of patients with different diseases, whereas disease-specific instruments are 
sensitive to key dimensions of quality of life that are impaired by specific diseases. An 
advantage of disease-specific instruments is that they increase acceptability of the ques-
tionnaire to the patient by including only relevant dimensions. A recommended research 
approach for assessing quality of life is the combination of generic and disease-specific 
instruments in order to combine the advantages of both methods (16-18). Of the studies 
assessing QOL in patients with venous thrombosis mentioned above, only one study 
used both a generic and a disease-specific instrument to measure quality of life (13). 
However, the authors failed to observe differences in the SF-36 scores between patients 
with and patients without the postthrombotic syndrome. 
 The aim of this study was to examine the impact of venous thrombosis on quality 
of life in a well-defined population of patients with venous thrombosis by using both a 
generic and a newly developed disease-specific measure. The aim of the present study 
was to study the relationship between quality of life, the presence of symptoms, and the 
presence of the postthrombotic syndrome. An additional aim was to test the disease-
specific questionnaire for a larger investigation.
 
 




Patients seen by one of the authors (MC) at the thrombosis clinic of the University of 
Vermont were considered for participation. Their charts were reviewed for eligibility and 
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the presence of postthrombotic syndrome. Individuals under age 18 or who had comor-
bid disease were excluded from the study. A total of 86 eligible patients were selected to 
participate in the study. Of the selected patients, 3 refused, 2 were deceased and 16 could 
not be reached. Following a telephone call by a research nurse 65 patients (75.6%) gave 
their consent to participate. The investigators contacted those 65 individuals by phone, 
and sent out the questionnaire and consent forms by mail. Non-responders received a 
reminder questionnaire. The research protocol was approved by the local institutional 




Demographic and illness related variables 
 
The questionnaire included the following: age, sex, marital status, employment status, 
number of episodes of thrombosis, location of thromboses, time elapsed since last 
thrombosis and a list of 11 symptoms that can be related to the postthrombotic syn-
drome. Patient charts were also reviewed to classify the presence of the postthrombotic 
syndrome as determined by a physician (MC). 
 
Quality of life 
 
As a generic quality of life instrument, the Short-Form 36 (SF-36) was used (19). The SF-
36 is the most widely used and evaluated generic instrument to measure quality of life 
(20). The SF-36 is a measure which assesses functional, psychological and social status. It 
consists of 36 items spread over 8 dimensions, plus a single item giving information on 
change in health over the past year. In addition to the 8 subscales, 2 summary scores can 
be calculated: the Physical Component Summary (PCS) and the Mental Component 
Summary (MCS). A major advantage of the SF-36 is its extensive application in several 
disease conditions and excellent psychometric characteristics. The SF-36 has population 
norms available against which the results of this study will be compared (21). 
As a disease-specific measure, a quality of life questionnaire developed by the au-
thors was used (see Appendix for sample items). The Venous Thrombosis-Quality of 
Life questionnaire (VT-QOL) was based on interviews held with thrombosis patients and 
previous QOL research in venous thrombosis (14;22;23). The final instrument consisted 
of questions assessing quality of life in the dimensions physical functioning (7 items, α = 
0.96), social functioning (6 items, α = 0.94), general mental health (6 items, α = 0.94) and 
thrombosis repercussions (6 items, α = 0.88). We chose this approach because according 
to the existing literature about QOL measurement in patients with venous thrombosis, to 
accurately measure quality of life, it is imperative to focus on physical, emotional and so-
cial functioning (24). All items were rated on a 5-point Likert scale. It is possible to calcu-
late subscores on all subscales with a range of 0 to 100 where 0 indicates worst possible 
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quality of life and 100 indicates best possible quality of life. This is in line with the scor-
ing of the SF-36. Additional questions were asked about the perceived severity of throm-




All data were entered and analyzed using SPSS 11.0. Means were calculated for all SF-36 
subscales and compared to U.S. population norms adjusted for age and sex, by means of 
t-tests. Patients were grouped in three different ways: patients with and without PTS, pa-
tients with and without a recent event (<2 years ago), and patients with 1, 2 or multiple 
events of venous thrombosis. To compare scores between groups, analysis of covariance 
(ANCOVA) was used and analyses were adjusted for age and sex. Simple univariate cor-
relations were used to detect relationships between subscales of the SF-36 and the 








A total of 45 out of 65 patients (69%) returned the questionnaire. The sample consisted 
of 13 men (28.9%) and 32 women (71.1%). The mean age was 44.1 years, with a range 
from 21 to 80 years. A total of 13 subjects were unemployed (28.9%), of whom 6 were 
unemployed due to disability (13.3%). Non-responders were more likely to be male and 
were slightly younger than responders. No differences were seen between the two groups 
regarding the type of thrombosis the patients had experienced.  
In the participant group, the number of patients with a recent thrombotic event, 
i.e. after 2000, was slightly lower. Respondents experienced between 1 and 8 thrombotic 
events, with a median of 2 episodes. All 45 respondents experienced their most recent 
thrombosis event between 1997 and 2002 with a median elapsed time of 2 years; 38% 
had their most recent thrombosis event after 2000.  
From chart review it was concluded that 20 subjects (44%) had no long-term 
physical effects from their venous thrombosis and 25 (56%) had mild or severe post-
thrombotic syndrome. There were no significant differences in the presence of the post-
thrombotic syndrome with respect to age, sex, number of venous thromboses and time 
elapsed since the last episode. Patients with PTS as diagnosed by a physician had a sig-
nificantly higher number of self-reported symptoms compared to patients without PTS 





Because our sample was composed of a higher proportion of women and was older than 
the group used for the general U.S. population norms (N= 2,463) (21), the U.S. popula-
tion norms were adjusted by weighting the norms with the age and sex distribution in our 
sample. The venous thrombosis patients scored significantly lower on all subscales of the 
SF-36 (see Figure 1). The scores on the Mental Health subscale are significantly lower at 




Quality of life 
PF: Physical functioning 
PR: Physical role limitations 
BP: Bodily pain 
GH: General health perceptions 
VT: Vitality 
SF: Social functioning 
ER: Emotional role limitations 
MH: Mental health 
 
Legend: 
Figure 1. Mean scores of venous thrombosis patients on the SF-36 compared to an 
U.S. population sample 
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Table 1 lists the means of the SF-36 subscales and summary scores for the three 
different groupings, namely: patients with a recent event and those with an event longer 
ago, patients with 1, 2 or multiple events, and patients with PTS and without PTS. To 
determine significant differences between the groups, analyses of covariance were per-
formed for the two summary scores. All analyses were adjusted for age and sex.  
The presence of PTS was associated with lower SF-36 summary scores, indicating 
a worse quality of life for patients with PTS. However, only the difference in mean scores 
on the Physical Component Summary reached statistical significance {PCS: F(1,39) = 
4.42,  p < 0.05, MCS: F (1,39) = 1.35, p = .25}. 
There is no significant relationship in quality of life scores between patients with 
a recent event and those without a recent event, when adjusted for PTS, although the 
Physical Component Summary is slightly lower for patients without a recent event and 
the Mental Component Summary is somewhat higher for this group {PCS: F (4, 38) = 
1.29, p = .29, MCS: F (4, 38) = 1.14, p = .35}. 
The number of thrombotic events the patients had experienced was divided into three 
groups (1, 2, or more than 2 events). A negative trend was observed between number of 
thrombotic events and Physical Component Summary.  These mean scores were not 
found to be significantly different when adjusted for PTS {F (5, 37) = .863, p = .52}.  
 
Table 2. Mean scores, standard deviations and Cronbach alpha’s on the venous-
thrombosis quality of life questionnaire (VT-QOL) and correlations with SF-36 
subscales for the venous thrombosis patient sample (N = 45) 



















(22.5) 0.92 .77** .69** .58** .32* .45** .50** .61** .50** 
General 
 Mental Health 
(0-100) 
75.0 





(24.9) 0.87 .51** .51** .51** .44** .52** .54** .49** .61** 
Pain (1-6) 
2.1 




(1.3)  -.05 .12 .24 -.03 .06 .03 -.07 -.12 
Restriction (1-3) 
1.5 
(0.5)  -.62** -.51** -.46** -.44** -.32* -.31* -.42** -.30 
* P < 0.05 
** P < 0.01 
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these trends failed to reach statistical significance.
Patients with a recent event have significantly lower scores on the physical func-
tioning and pain subscales of the VT-QOL, after adjusting for PTS {physical function-
ing: F(4,36) = 2.92, p < 0.05; pain: F(4,36) = 2.67, p < 0.05} The other subscales did not 
reach statistical difference. A significant negative trend in scores was observed between 
number of thrombotic events and scores on the physical limitations {F(5,37) = 2.83, p < 
0.05} and thrombosis repercussions subscales {F(5,37) = 2.86, p < 0.05}. This negative 
trend was less obvious in the other subscales. A positive trend in scores could be ob-
served in pain and restriction in daily activities (meaning that patients with more throm-
botic events experience more pain and are more restricted in their daily life) but  
Patients with PTS have significantly lower scores on most VT-QOL than subjects 
without PTS, except for general mental health, perceived severity and restriction in daily 
activities {physical functioning: F(3, 39) = 3.43, p < 0.05; thrombosis repercussions: 
F(3,39) = 3.42, p < 0.05; social functioning: F(3,39) = 2.98, p < 0.05; pain: F(3,39) = 
2.87, p < 0.05}. 
To determine significant differences on the VT-QOL between the groupings (pa-
tients with and without PTS, patients with and without a recent event and patients with 
1, 2, or multiple events), analyses of covariance were performed for all subscales. All 
analyses were adjusted for age and sex. Mean scores are listed in Table 3. 
Mean scores, standard deviations and Cronbach alpha’s on the disease-specific question-
naire (N = 45) are shown in Table 2, along with correlations between the subscales of 
this disease specific measure and the subscales of the SF-36. Cronbach alpha’s for all 
subscales are high (0.87-0.96), indicating a good internal consistency of the subscales. 
There were strong correlations of scores of the VT-QOL and SF-36 scores.  In addition, 
pain and restriction in daily activities were significantly correlated with most subscales, 
especially physical functioning, physical role limitations and bodily pain. Perceived sever-
ity did not correlate significantly with any of the SF-36 subscales.  
 
 
Venous thrombosis- quality of life questionnaire (VT-QOL) 
 
GH: General health perceptions   MH: Mental health 
BP: Bodily pain     ER: Emotional role limitations 
PR: Physical role limitations   SF: Social functioning 
PF: Physical functioning    VT: Vitality 
Legend Table 2  









































































































































































































































































































































































































































The results of this study indicate that the quality of life of patients with venous thrombo-
sis is impaired in all domains. This impairment encompasses physical, social and psycho-
logical domains. Compared to a general U.S. population sample, venous thrombosis pa-
tients scored significantly lower on all subscales of the SF-36 after adjusting the popula-
tion norms for the age and sex distribution in the sample. The subjects in our study had 
their last thrombotic event a median of 2 years ago, which indicates that even after some 
years, quality of life of patients with venous thrombosis is still impaired.  
 Given our results on both the SF-36 and thrombosis-specific instrument we can 
also conclude that quality of life impairment is related to the presence of self-reported 
symptoms and the presence of the postthrombotic syndrome as reported by a physician. 
Both findings are consistent with earlier research (12-15). From our results on the VT-
QOL can also be concluded that the quality of life of venous thrombosis patients is more 
impaired after multiple events. A study by Kahn and colleagues (13) found that the post-
thrombotic syndrome had a significant impact on quality of life as measured by the dis-
ease-specific measure VEINES-QOL but no differences were observed in the SF-36 
scores. In our study however, we did detect significant differences (p < 0.05) in the 
Physical Health Component score between subjects with and subjects without the post-
thrombotic syndrome. On our venous thrombosis-quality of life questionnaire, those dif-
ferences were even more obvious and were found across almost all dimensions. A reason 
for this could be that most patients in our study had experienced more than one throm-
botic event, whereas in the study by Kahn et al., patients with recurrent venous thrombo-
sis were excluded. Accordingly the patients in our study might have had more severe 
manifestations of PTS.  
 The disease-specific QOL measure that we used in this study, the VT-QOL, was 
developed by our group and has not been formally evaluated for reliability and validity 
before, because the present study was the first study to use and validate this question-
naire. However, the good internal consistency and high correlations with the SF-36 sub-
scales in this study give encouraging evidence for its reliability and validity and its future 
use. Its advantage to the SF-36 is the fact that it seems to be more sensitive to the spe-
cific problems venous thrombosis patients are facing, which can be concluded from its 
ability to detect differences between patients with and patients without PTS. Further-
more, unlike the SF-36, the instrument was able to discriminate between patients with 
one or multiple events and patients with or without a recent event.  
 When interpreting the results of this study, some limitations should be taken into 
consideration. We excluded patients with comorbid conditions such as cancer to avoid 
confounding by conditions that could affect quality of life in other ways. This could limit 
the generalizability of our study, but it is unlikely that it has affected the major conclu-
sions. Non-responders were more likely to have experienced a recent thrombotic event, 
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which might have influenced the results, although time since last event was not found to 
be significantly associated with QOL. Presence of PTS is best determined for research 
purposes by a known scale such as the CEAP classification (25). In our study, however, 
presence of PTS was determined by a single clinician at different points in time prior to 
the QOL assessment. The strong correlation between the classification of PTS by the 
clinician and the self-reported symptoms at the time of QOL determination suggests 
minimal impact of this possible confounding factor. Use of a single observer probably 
minimized the possibility of misclassification of PTS.  
 Given the observed impact of venous thrombosis and the postthrombotic syn-
drome on quality of life, assessment of QOL should be included in future studies on the 
outcomes of venous thrombosis, preferably with a disease-specific measure like the VT-
QOL. Venous thrombosis is a multi-causal disease that is caused by both genetic and en-
vironmental factors (26). Future studies might also assess the impact of genetic testing 
for thrombophilia on quality of life. For clinical care, our results indicate that health care 
givers should be sensitive about the impact of venous thrombosis on the well-being of 
their patients. 
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Appendix 
Sample items of the venous thrombosis- quality of life questionnaire (VT-QOL): 
During the past 4 weeks, to what extent did your thrombosis problem limit you while 












to do so 
Physical functioning      
Finding a comfortable position to 
sleep 1 2 3 4 5 
Standing for a long time 1 2 3 4 5 
Social functioning      
Social or leisure activities in which 
you are standing for long periods 
(e.g. parties, weddings, shopping etc.)
1 2 3 4 5 
Social or leisure activities in which 
you are sitting for long periods (e.g. 
going to the cinema or theatre) 




A little Moderately A lot Absolutely
General mental health      
I feel on edge 1 2 3 4 5 
I feel I am a burden to others 1 2 3 4 5 
Thrombosis repercussions      
I am frustrated about my thrombosis 1 2 3 4 5 
I am worried about my future be-
cause of my thrombosis 
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Objective: The aim of this study was to examine how illness perceptions influence the 
quality of life of patients with venous thrombosis, a medical condition that has had 
hardly been subject of psychosocial research.   
Methods: Forty-five patients with a history of venous thrombosis from the University of 
Vermont in Burlington, VT, USA, filled out a mailed questionnaire containing the Short-
Form 36 (SF-36) and the Illness Perception Questionnaire-Revised (IPQ-R). 
Results: Quality of life of these patients was impaired compared to general population 
norms. Regression analyses showed that scores on the IPQ-R subscales, especially time-
line acute/chronic, personal control and identity, and the cause ‘heredity’ were able to 
explain a significant amount of variance in quality of life scores after controlling for ill-
ness-related variables.  
Conclusion: QOL impairment in patients with venous thrombosis can be explained by 
illness perceptions. Further research could investigate the role of illness perceptions in 
patients with a genetic vulnerability to venous thrombosis, and the effects of psychoso-





Venous thrombosis is the result of the formation of a blood clot in a vein. This clot is 
called a thrombus and blocks the flow of blood in the affected vein. The symptoms of 
venous thrombosis include pain, swelling, redness, and tenderness of the skin. Venous 
thrombosis is most common in the veins of the legs, but it can also occur in other veins. 
It is a common complication among hospital inpatients and contributes to longer hospi-
tal stays, morbidity, and mortality. The annual incidence of diagnosed venous thrombosis 
in western countries is 1 in 1000 persons (1). Venous thrombosis of the lower limb usu-
ally starts in the veins of the calf. In about 10-20% of patients, the venous thrombosis 
extends above the knee. Fatal pulmonary embolism occurs in 1-5% of patients with ve-
nous thrombosis (2). Between 20 and 50% of patients with symptomatic venous throm-
bosis develop the postthrombotic syndrome (PTS), which consists of chronic discomfort 
in the affected leg or arm and is characterized by swelling and pain, and occasionally vari-
cose veins and leg ulceration (3). Venous thrombosis is a multi-causal disease, caused by 
both genetic and environmental risk factors (4).  
Quality of life in relation to health (QOL), may be defined as ‘the functional effect of an 
illness and its consequent therapy upon a patient, as perceived by the patient’ (5). The 
domains that contribute to this effect are physical, psychological, and social functioning. 
Until recently, quality of life in patients with venous thrombosis was an unstudied area. 
Studies have now indicated that patients with venous thrombosis suffer from impaired 
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physical functioning and have low perceptions of their health. On average, QOL im-
proves in the first four months after venous thrombosis, but in about one third of pa-
tients, QOL remains poorer than population norms, especially in patients who have the 
postthrombotic syndrome (6-9). 
 Quality of life in patients with chronic illness has been studied extensively, and 
research has shown that the level of disability as experienced by the patient can not al-
ways be explained merely by biomedical variables. Therefore, research on quality of life 
has focussed on other factors that could potentially influence the perceived impact of the 
illness. The patient’s own perceptions of an illness were found to play an important role 
in explaining quality of life. Leventhal’s Common Sense Model (CSM) of health and ill-
ness behaviour is a model that describes a system with two parallel pathways that interact 
when a patient adapts to an illness or health threat (10;11). Components of the first 
pathway are the cognitive representations of an illness. Those representations (also called 
illness perceptions) include five key attributes: the label and symptoms that patients asso-
ciate with their illness (identity), and their beliefs about the etiology (cause), the outcome 
(consequences), the duration (timeline) and the controllability (cure/control) of the ill-
ness (10;12). The second pathway involves the emotional response to an illness. To-
gether, these illness perceptions can lead to a diverse array of health outcomes, possibly 
through coping behaviours. Quality of life factors can represent important outcome 
components of the Common Sense Model. The influence of the illness perceptions on 
the quality of life of patients with a chronic disease has been investigated in a number of 
studies. These studies have provided support for the hypothesis that a strong illness iden-
tity (the attribution of many symptoms to an illness), as well as a belief in a long duration 
and serious consequences of an illness have a negative effect on the well-being of pa-
tients (13;14).  
 Most previous studies using the CSM have only investigated the cognitive com-
ponents of patient’s perceptions, largely overlooking the emotional component (15;16). 
To solve this, in the revised version of the Illness Perception Questionnaire (IPQ-R), 
which was used in this study, a subscale was added to assess emotional responses, such as 
anxiety and anger, generated by an illness (16). The revised version of the IPQ also in-
corporates a new subscale called ‘illness coherence’. This subscale was added to assess 
the extent to which the illness ‘makes sense’ to the patient. 
 Illness perceptions in patients with cardiovascular diseases have been studied to 
some extent, but none of these studies dealt with venous diseases (14). Examining pa-
tients with venous thrombosis from a biopsychosocial perspective is highly relevant, be-
cause these patients not only have to deal with the consequences of their illness, but also 
with the self-management of their anticoagulation treatment. A better understanding of 
the patient’s perceptions of their illness may help in improving compliance to long-term 
treatment. In addition, many patients who have suffered from venous thrombosis, have a 
genetic coagulation disorder which predisposes to thrombosis. As in similar conditions 
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such as hypercholesterolemia, attention should be paid to the psychological impact of 
testing for these disorders (17). 
 The aim of this cross-sectional study was to describe the cognitive and emotional 
illness perceptions that patients with venous thrombosis form about their illness and to 







Patients with a history of venous thrombosis seen by one of the authors (MC) at the 
thrombosis clinic of the University of Vermont in Burlington (VT, USA) were consid-
ered for participation. All patients had been referred for evaluation and management of 
venous thrombosis. Eligibility was assessed through chart review, and individuals under 
the age of 18 or who had comorbid disease were excluded from the study. A total of 86 
patients were selected to participate. Of the selected patients, 2 patients were deceased, 
16 patients could not be reached and 3 patients refused to participate. A research nurse 
obtained verbal consent to participate from 65 patients (75.6%). The investigators con-
tacted those 65 individuals by phone, and sent out the questionnaire and consent forms 
by mail. Non-responders received a reminder questionnaire. The research protocol was 




Demographic and illness related variables 
 
The questionnaire included the demographic variables age, sex, marital status, and em-
ployment status. The number of thrombotic events, the presence of the postthrombotic 
syndrome and the time (in years) elapsed since last the last thrombotic event were in-
cluded as illness related variables. The presence of PTS was specifically evaluated in the 
clinic and recorded through chart-review. 
 
Quality of Life 
 
The Short-Form 36 (SF-36) was used to measure quality of life (18). The SF-36 is the 
most widely used generic QOL instrument assessing physical, psychological and social 
functioning (19). It consists of 36 items spread over the dimensions of physical function-
ing, physical role limitations, bodily pain, general health perceptions, vitality, social func-
tioning, emotional role limitations and mental health. Major advantages of the SF-36 are 
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To measure illness perceptions, the revised version of the Illness Perception Question-
naire (IPQ-R) was used, which is a measure based on the CSM (16). In the IPQ-R, the 
identity scale consists of 14 general symptoms and asks patients to state whether or not 
they have experienced a particular symptom since the beginning of their illness and 
whether they believe this symptom is related to their illness. The number of illness-
related symptoms forms the identity subscale (possible range 0-14). In the following sec-
tion, the timeline acute/chronic, timeline cyclical, consequences, personal control, treat-
ment control, illness coherence and emotional representations subscales are rated on a 5-
point Likert type scale. The total number of items in this section is 38. To calculate 
scores for each subscale, scores of the items in each subscale were added and the total 
was divided by the number of items in the subscale (possible subscale range 1-5). The last 
section presents the causal dimension, consisting of 18 separate items rated on the same 
5-point Likert scale. An open ended question at the end of the causes section asks pa-







Forty-five of the 65 questionnaires sent out were returned (69%). The patient sample 
consisted of 13 men (29%) and 32 women (71%). The mean age was 44 years, with a 
range from 21 to 80 years. The subjects had experienced between 1 and 8 thrombotic 
events with a median of 2 events. Their last thrombotic event had occurred between 
1997 and 2002 with a median elapsed time since the last event of 2 years. Twenty-five 
subjects (56%) had mild or severe PTS and 20 subjects (44%) did not have PTS. 
The characteristics of the patients that returned the questionnaire (N=45) were com-
pared to the characteristics of the patients that refused to participate (N=3) or that did 
not return the questionnaire (N=20). Non-responders were more often men (54%), and 
slightly younger than responders (mean age 39 years). The number of patients with a re-
cent event (after 2000) was slightly lower in the participant group (38% vs. 46% in the 
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Quality of Life 
 
Compared to population norms of a general U.S. population (N=2,463) (18), the group 
of venous thrombosis patients scored significantly lower on all subscales of the SF-36 
(see Figure 1). To adjust for the higher proportion of women and older people in our 
sample, we adjusted the U.S. population norms by weighting the norms with the age and 
sex distribution in our sample (8). Significance was assessed by means of t-tests and dif-
ferences in scores were found to be significant for all subscales (p < 0.05). 
 
 
Figure 1. Mean scores of venous thrombosis patients (N = 45) and norms of a 






















PF: Physical functioning 
PR: Physical role limitations 
BP: Bodily pain 
GH: General health perceptions 
VT: Vitality 
SF: Social functioning 
ER: Emotional role limitations 




Means, standard deviations and intercorrelations between the IPQ-R subscales are de-
picted in Table 1. The reliability of all subscales, was satisfactory (all Cronbach α’s > 
0.76). Patients attributed a mean of 2.29 out of 14 symptoms of the identity subscale to 
their venous thrombosis. Most subjects (44%) reported no symptoms at all, 40% re-
ported between 1 and 3 symptoms, and 16% reported that 6 or more symptoms were 
related to venous thrombosis.  The symptom that was attributed to venous thrombosis 
most often was pain (46%), followed by fatigue (18%), breathlessness (13%) and sleep 
difficulties (13%).  
 On all other subscales, mean scores were between 2.49 and 3.40 (see Table 1). 
Respondents believed that their illness would be prolonged and that their symptoms 
were not cyclical. They believed in some personal and treatment control over their illness, 
and had a moderately coherent view of their illness. The emotional impact of their illness 
was also moderate.  
 The perceived causes of venous thrombosis reported most frequently by the par-
ticipants (participants agreed or strongly agreed with the cause) were ‘Hereditary-it runs 
in my family’ (38%), while 40% thought the occurrence of thrombosis represented 
‘chance or bad luck’. In the open-ended question, 20% of participants mentioned hor-
mone replacement therapy or oral contraceptives as a cause, and 28% mentioned bed 
rest, immobilization or surgery as a cause.  
 To detect relationships among the illness perceptions, Pearson correlations be-
tween the subscales were computed (see Table 1). These correlations show that patients 
with a strong illness identity (those who attribute more symptoms to venous thrombosis) 
believed in a longer duration of their illness, more serious consequences, less control of 
treatment and had stronger representations of emotional distress. A belief in a longer du-
ration of the illness (patients with a higher score on timeline acute/chronic) was related 
to a belief in more serious consequences, less treatment control and stronger representa-
tions of emotional distress. Patients who reported that the symptoms of their illness were 
cyclical reported less illness coherence and stronger representations of emotional distress. 
Also, strong representations of emotional distress were correlated with lower illness co-
herence, less treatment control and had a strong relationship with the perception of more 
serious consequences.  
 A significant correlation (r =0.31, p < 0.05) was found between the number of 
thrombotic episodes a respondent had, and the score on the consequences subscale. The 




Chapter 4 Illness perceptions and outcome 
 65
 

























































































































































































































































































































































Chapter 4 Illness perceptions and outcome 
 
 
 Older respondents had a lower illness identity than younger patients (r = -.42, p 
< 0.01), meaning that they attributed fewer symptoms to venous thrombosis. There were 
no significant differences between men and women with respect to the illness perception 
subscales. Patients with PTS attributed more symptoms to their illness, believed in a 
longer timeline and had a lower understanding of their illness. However, the statistical 
significance of these differences was only marginal with a p < 0.1 level. 
 
Illness perceptions and quality of life 
 
Pearson correlations were computed between the illness perceptions and the subscales of 
the SF-36 (See Table 2). Illness identity, timeline acute/chronic and consequences had a 
negative correlation with most subscales of the SF-36. This indicates that patients who 
attributed more symptoms to venous thrombosis, who saw their illness as more chronic 
or perceived more serious consequences of their illness, had a lower quality of life scores. 
Patients who saw their illness as uncontrollable by themselves (personal control) scored 
significantly lower on the mental health and emotional role limitations. To examine the 
role of illness perceptions on the quality of life of patients with venous thrombosis, a se-
ries of stepwise regression analyses was conducted with the eight SF-36 subscale scores 
as dependent variables. Because of the small sample, an initial series of stepwise regres-
sion analyses was conducted to examine which illness related and demographic variables 
(age, sex, number of thrombotic episodes, time elapsed since the last event and presence 
of PTS) contributed significantly to the explanation of variance in SF-36 scores. Only the 
presence of PTS and the number of thrombotic episodes were found to contribute sig-
nificantly to the equation in some of the SF-36 subscales (physical functioning, and pain). 
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Table 2. Pearson correlations between the illness perceptions subscales (IPQ-R) and SF-
36 subscales 
 
 SF-36 subscales 
IPQ-R 
Subscales 
PF PR BP GH VT SF ER MH 
 Illness identity -.30 -.38* -.24 -.35* -.38* -.32* -.33* -.31 
Timeline                  
acute/chronic 
-.43** -.41** -.41** -.46** -.39* -.33* -.33* -.36* 
 Timeline cyclical -.29 -.21 -.24 -.08 -.10 -.20 -.16 -.16 
 Consequences -.34* -.32* -.21 -.31* -.28 -.28 -.36* -.33* 
 Personal control .15 .14 .26 .08 .32 .31 .34* .34* 
Treatment con-
trol 
.28 .31* .33* .20 .31 .22 .24 .19 
 Illness coherence .11 .00 -.05 -.13 -.24 -.14 .00 -.11 
 Emotional 
    representations 
-.29 -.32 -.11 -.06 -.19 -.10 -.23 -.25 
 
* p < .05  
** p <  .01  
Legend: For SF-36 subscales: see Figure 1 
 
  In the second series of analyses (see Table 3), presence of PTS and number of 
thrombotic episodes were entered in step 1 to control for possible confounding effects 
of these factors, and illness perceptions were entered in step 2, using the forward step-
wise procedure. In addition, the causes for venous thrombosis that were mentioned most 
often by the participants (hereditary and chance or bad luck) were entered stepwise in 
step 2 as well. Results of these analyses indicate that the presence of PTS and the number 
of thrombotic episodes explained a modest amount of variance in SF-36 scores. In scores 
on the subscale bodily pain, they contributed the most to the regression equation (12%), 
but this contribution was not significant. Of the IPQ-R, the subscales timeline 
acute/chronic, personal control and, to a lesser extent, identity and the cause “heredity” 
were the strongest predictors of quality of life as measured by the subscales of the SF-36. 
The IPQ-R subscales had the strongest contribution to the variance of the mental health 
subscale. On this subscale, the IPQ-R subscales personal control, timeline, and the cause 
hereditary accounted for 41% of explained variance. Also on the subscales vitality, bodily 
pain, and emotional role limitations, the IPQ-R subscales were good predictors, contrib-
uting 36%, 35% and 32% to the explained variance, respectively. 
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Table 3. Stepwise regression analyses with SF-36 scores as dependent variables and ill-
ness perceptions as predictors 
Presence of the postthrombotic syndrome and number of thrombotic episodes were forced into 
step 1, illness perceptions were entered stepwise in step 2. The adjusted R square was used to 
control for the number of variables entered. The table presents the variables in the final model. 
 
Criterion Variable Β Change R
2 adj. 
No. of episodes 




Timeline -.43** .09 
Physical functioning 
 
Personal control .31* .08 
No. of episodes 
Presence of PTS 
-.17 
.01 
.01 Physical role limitations 
Identity -.41* .13 
No. of episodes 




Personal control .43** .08 
Bodily pain 
Timeline -.42** .14 
No. of episodes 
Presence of PTS 
-.10 
-.00 
.00 General health perceptions 
Timeline -.43** .15 
No. of episodes 




Identity -.31* .12 
Personal control .48*** .13 
Vitality 
Timeline -.44** .15 
No. of episodes 




Personal control .45** .09 
Social functioning 
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Table 3, continued 
 
Criterion Variable Β Change R
2 adj. 
No. of episodes 




Personal control .49*** .16 
Timeline -.36* .07 
Emotional role limitations 
Identity -.31** .07 
No. of episodes 




Cause: hereditary -.33* .14 
Personal control .50*** .14 
Mental health 
Timeline -.42** .13 






In this study, patients with venous thrombosis from a thrombosis clinic in Vermont, 
USA, had an impaired quality of life on all subscales of the SF-36 as compared to a gen-
eral U.S. population.  Most patients did not attribute many symptoms to their illness as 
measured by the identity subscale of the IPQ-R. An explanation for this may be that the 
symptoms in the identity subscale are not symptoms that are commonly associated with 
venous thrombosis, which is a condition characterized by pain, swelling, redness and 
tenderness of the affected body-part, of which pain is the only symptom that is incorpo-
rated in the identity subscale. The venous thrombosis patients in this sample believed 
that their illness would be prolonged and that their symptoms were not cyclical. These 
beliefs are consistent with medical evidence that in most people, acute complaints of ve-
nous thrombosis will disappear over time.  
 Compared to a sample of patients with atrial fibrillation (a heart-condition that 
gives an increased chance of stroke, and can result in symptoms like breathlessness, pal-
pitations and fatigue) (20), our sample of venous thrombosis patients believed their ill-
ness to be more serious and of longer duration. Beliefs about the curability of the illness 
were similar in the two groups. 
 The perceived causes reported most frequently by the participants were ‘Heredi-
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tary-it runs in my family’ and ‘chance or bad luck’. The explanation to the perception of a 
hereditary cause could be that many people who develop venous thrombosis have a ge-
netic coagulation disorder (21). The fact that many people attributed their venous throm-
bosis to chance could be due to the fact that venous thrombosis is a multi-causal disease, 
caused by both genetic and environmental risk factors (4), and thus occurs in a wide 
range of clinical and life circumstances. In future research on illness perceptions in pa-
tients with venous thrombosis, causes that are specific to venous thrombosis should be 
added to the causal dimension of the IPQ-R. For instance the use of oral contraception, 
surgery, and immobilization could be included, as these causes are mentioned often in 
the open ended question about the causes, and are known risk factors for venous throm-
bosis (22).  
 We hypothesized that patients with PTS would attribute more symptoms to their 
illness and would believe in a longer duration and more serious consequences than pa-
tients without PTS. We found marginal support (p < 0.10) for the first two hypotheses 
only. Another unpredicted difference we found was that patients with PTS have a less 
coherent view of their illness. Possibly this is because the patients expected their symp-
toms to disappear after some time and became confused when the complaints persisted. 
 The patterns of correlations seen among the illness perceptions subscales are 
consistent with those reported by earlier research using the IPQ, which studied patients 
with myocardial infarction (23), multiple sclerosis (24) and irritable bowel syndrome (25). 
A sample of patients with an acute illness, myocardial infarction (MI) (23), also showed a 
significant correlation between the number of symptoms attributed to their disease and 
the seriousness of the disease. However, in our sample of venous thrombosis patients, 
this correlation was stronger than in the sample of MI patients (.50 vs .26). This could be 
due to the fact that in general, these venous thrombosis patients attributed less symp-
toms to their illness (mean 2.29 vs. mean 7.8 in the MI sample), or because the patients 
experienced venous thrombosis an average of 2 years prior to the survey. Patients who 
still experience multiple symptoms 2 years after their last event, perceive the conse-
quences of their illness as more severe. This same effect was noted again in the sample of 
patients with irritable bowel syndrome (IBS) (25). One difference in results was found: in 
our sample the timeline and treatment control subscales were negatively correlated while 
a positive association was found in the IBS sample. This is probably due to the fact that 
patients with a chronic condition such as IBS learn to deal with their illness after some 
time, whereas patients with venous thrombosis expect their symptoms to disappear over 
time.  
 Regression analyses showed that illness perceptions were able to explain a signifi-
cant amount of variance in quality of life scores. We hypothesized that belief in a longer 
duration and more serious consequences would be the best predictors of quality of life, 
and that patients with a low understanding or high emotional representations would ex-
perience a more impaired quality of life. However, the dimensions that explained most of 
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the variance were timeline acute/chronic, personal control, identity and the heredity 
cause. Unexpectedly, the subscales illness coherence and emotional representations did 
not correlate significantly with any of the SF-36 subscales, nor did they contribute to the 
regression equations. Since patients with PTS scored lower on the illness coherence sub-
scale, and patients with PTS had lower QOL scores in all domains, the fact that illness 
coherence does not seem to play a role in the explanation of QOL in these patients, is 
noteworthy. It indicates that for these patients, not having a coherent understanding of 
their illness does not impact on their quality of life. It is interesting to note that the “he-
redity” cause explained a significant amount of variance in the mental health subscale. 
This gives an indication that a known or suspected genetic risk factor for venous throm-
bosis might have a negative impact on psychological well-being.  
 The main limitations of this study are the small sample size and the fact that the 
sample was taken from only one thrombosis clinic in the Northeastern USA. Patients 
were referred and generally had genetic testing performed, so we could not analyze the 
influence of genetic testing on results. This makes it difficult to generalize our findings to 
other thrombosis patients so results of this study should be replicated with other and lar-
ger venous thrombosis populations. Another limitation is the cross-sectional nature of 
the study, which makes it harder to be confident about the interpretation of the explana-
tion of variance in quality of life by the illness perception components.  
 Our study indicates that the three domains of quality of life can help to define the 
outcome component of the Common Sense Model. Further research using the IPQ-R 
should focus primarily on the contribution of the new subscales since this study does not 
give an indication for their significant effects on quality of life in patients with venous 
thrombosis, but they might influence other outcomes that were not within the scope of 
this study. Further research on illness perceptions in venous thrombosis patients should 
adopt a longitudinal design to assure the causal direction of the effects, in which illness 
perceptions are measured at baseline and outcome is measured on a subsequent occasion. 
Also, there should be research on the psychological impact of a genetic vulnerability for 
venous thrombosis, since this study gives an indication that this might influence quality 
of life. And finally, an intervention study, like that of Petrie and colleagues (26), could be 
conducted to investigate the impact of a short intervention focused on changing illness 
perceptions on the well-being of patients with venous thrombosis. For clinical care spe-
cifically, our results suggest that health care providers might improve the quality of life of 
these patients by addressing the illness perceptions of patients. This would specifically be 
more useful for patients with PTS, since this is a group that seems to be more vulnerable 
than patients without PTS.  In these patients, dealing with duration beliefs and treatment 
and self-management issues seems to be most advantageous. A biopsychosocial perspec-
tive could help patients with venous thrombosis by making both health care profession-
als and family members of patients more aware of the impact of venous thrombosis on 
daily life and the role that illness perceptions play in quality of life. Furthermore, it could 
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play a role in assisting these patients to adjust to the self-management of their anticoagu-
lation treatment (27). 
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Background: Little research has been done regarding the psychological consequences of 
knowing that one is at an increased risk for venous thrombosis.  
Objectives: The aim of this study was to explore attitudes towards genetic testing for 
protein C deficiency.  
Methods: Questionnaires about genetic testing attitudes, dispositional anxiety, risk per-
ception, and thrombosis-related worry, were completed by 168 asymptomatic members 
of a North-American kindred with a high prevalence of heritable protein C deficiency 
conferring a high life-time risk of venous thrombosis. A total of 76 subjects (45%) had 
not been tested for protein C deficiency before participating in our study whereas the 
other 92 subjects (55%) had been tested prior to filling in the questionnaire, of whom 34 
people had protein C deficiency, while 58 did not.  
Results: Family members with protein C deficiency perceived a higher risk of suffering 
venous thrombosis and scored higher on thrombosis-related worry than family members 
without protein C deficiency. Participants who had not been tested did not report exces-
sive thrombosis-related worry. Participants with protein C deficiency reported a belief in 
the psychological and health benefits of testing, and felt they experienced low psycho-
logical distress following the genetic test. High psychological distress following the test 
was related to dispositional anxiety and thrombosis-related worry. Participants without 
protein C deficiency were relieved after finding out they did not have the deficiency.  
Conclusion: There seem to be few negative psychological consequences of knowing that 





The number of inherited disorders and risk factors that can be detected through genetic 
testing is increasing rapidly, and genetic testing is becoming a common component of 
routine medical care. Recently, genetic testing is being applied to detect personal suscep-
tibility to disease, in the belief that awareness of genetic risk will enhance informed medi-
cal decision making and have an impact on changing health behaviour (1). 
Quality of life in patients with venous thrombosis is impaired compared to a 
healthy population, especially in the presence of the postthrombotic syndrome. This im-
pairment encompasses the physical, social and psychological domains of quality of life 
(2;3). Venous thrombosis is a multi-causal disease caused by both genetic and acquired 
risk factors (4;5). Examples of acquired risk factors are older age, the use of oral contra-
ceptives, hormone replacement therapy, pregnancy, and immobilization. The discovery 
of genetic risk factors for venous thrombosis,  and the widespread clinical application of  
genetic screening, has engendered a debate regarding the pros and cons of thrombophilia 
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testing (6;7). Generally, it is believed that widespread screening for thrombophilia is not 
justified because it is not cost-effective. However, some believe screening of patients at a 
high risk of venous thrombosis is likely to be useful because it may improve clinical out-
come through changes in the appropriate use and duration of therapy. It is reasoned that 
family screening of individuals with a close relative with thrombophilia can help to opti-
mize prophylactic treatment of asymptomatic carriers in high-risk situations (i.e. during 
surgery or pregnancy in which they would normally not receive treatment)(8). To date, 
there are no data supporting this view. Opponents of widespread screening have pointed 
out that it may lead to psychological distress. However, little research has focused on the 
psychological consequences of knowing that one is at an increased risk for venous 
thrombosis. This is notable because carriership of a genetic deficit may influence daily 
life, since it can cause considerable distress. Research on the psychological influence of 
genetic testing has focused mainly on single gene conditions such as Huntington’s disease 
and on hereditary cancers. Findings suggest that individuals undergoing predictive ge-
netic testing do not experience considerable long-term psychological distress (9;10). 
However, individuals with a high predisposition to depression or anxiety may be more 
vulnerable to adverse effects (1;11). Possible negative effects of a positive test result in-
clude anxiety and depression following the test, worry about the future and about the 
possibility of passing the genetic defect on to children. Furthermore, positive test results 
might cause stigmatization, problems with insurance, and they can interfere with medical 
decision making. To our knowledge only three previous publications have dealt with the 
subject of the social and psychological impact of awareness of carriership of thrombo-
philia. The first study investigated women’s reactions to awareness of activated protein C 
(APC) resistance carriership in 270 women (12). In this study, women were asked to an-
swer questions about the way their knowledge of APC resistance has affected them, in a 
yes/no format. The study concluded that most women were pleased with having been 
informed of their status. The majority of women (84%) found that their awareness of 
APC resistance might be an advantage in the event of future operations or accidents, and 
69% reported that their lives were unaffected by the knowledge of APC resistance.  
However, 27% of the women reported that they had become more worried, and 10% 
was afraid to get pregnant again. The second study, by Hellmann and colleagues, used a 
questionnaire with a Likert-scale to examine patient experience of genetic testing for fac-
tor V Leiden (FVL) in 110 patients and found that 43% of the patients experienced in-
creased worry (13). In addition, they reported that patients indicated concern with the 
lack of available information about FVL. The discrepancy in the reported worry rates of 
these two studies might be explained by the difference in methodology between the two 
studies. A Likert scale allows participants to be more specific in their responses, rather 
than having to choose between two endpoints in a yes/no format. 
 The third study on this subject explored the psychological and social aspects of 
asymptomatic carriership of the factor V Leiden mutation in a qualitative study. After 
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interviewing 17 individuals, the authors concluded that carriership of FVL has the poten-
tial to influence daily life by inducing concerns, stigmatization and problems with insur-
ance eligibility (14).  
The results of these three studies need to be replicated and clarified in more 
structured studies which assess the psychological impact of genetic testing for thrombo-
philia and factors that might influence this impact. 
Protein C is a vitamin K dependent protein that, upon activation to activated 
protein C (APC) inhibits thrombus formation by inactivating the coagulation factors Va 
and VIIIa.  Deficiency of protein C was one of the first genetic risk factors associated 
with hereditary thrombophilia (15). The lifetime risk for venous thrombosis in protein C 
deficient individuals is about 10-fold increased compared to the normal population (16). 
Protein C deficiency is caused by a wide variety of mutations in the protein C gene. The 
present study investigates a large kindred of French-Canadian descent with protein C de-
ficiency caused by a 3363 C insertion mutation (17). 
 The aim of this study was to explore the attitudes of protein C deficient individu-
als about genetic testing and to assess their perception of their thrombotic risk and their 
thrombosis-related worry. Furthermore, we tried to establish the role of trait anxiety in 
these attitudes to test the hypothesis that, as in earlier research on predictive genetic test-
ing, individuals with a higher psychological vulnerability experience more psychological 
distress following the genetic test. Age and sex differences were assessed because older 
age and female hormones are risk factors for venous thrombosis. In addition, we as-
sessed the knowledge of participants about the other risk factors for venous thrombosis, 
and the relationship of this knowledge with risk perceptions, thrombosis-related worry 







The ascertainment and evaluation of the family members participating in this study was 
described previously (18). Members of the kindred were contacted by phone by one of 
the investigators (SN) and an appointment was made to meet with the investigators. At 
this appointment, several questionnaires were completed. All participating subjects gave 
informed consent. The study protocol was approved by the Human Experimentation 
Committee of the University of Vermont College of Medicine, Burlington (VT, USA). 
Inclusion criteria stipulated that participants had to be over age 18, and physically and 
mentally capable of completing the questionnaire. Participants were divided into three 
groups: participants who had not been tested before (group 1), participants with protein 
C deficiency (group 2), and participants without protein C deficiency (group 3). Most of 
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Risk perception: Perceived risk of venous thrombosis was assessed with two items  
1. How likely do you think it is that, at some point in your life, you will get thrombosis? 
2. How vulnerable do you think you are to getting thrombosis at some point in your life? 
Each item was rated on a 7 point Likert scale ranging from 1 (not at all) to 7 (almost certain 
or extremely) and summed to generate risk perception scores. 
Worry: Worry about venous thrombosis was assessed with two items: 1. To what extent 
are you worried about getting thrombosis? 2. To what extent are you concerned about 
getting thrombosis? Each item was rated on a 7 point Likert scale ranging from 1 (not at 
all) to 7 (extremely) and summed to generate worry  scores. 
Trait anxiety: As a measure of dispositional anxiety the trait form of the State-Trait Anxi-
ety Inventory (STAI) (form Y-2) was included (19). This is a 20-item questionnaire that 
measures relatively stable individual differences in anxiety proneness. All items are rated 
on a scale from 1 (not at all) to 4 (very much so). 
Knowledge about risk factors for venous thrombosis: To assess the knowledge of participants 
about the acquired risk factors for venous thrombosis, a scale with 8 items was used, on 
which participants had to rate on a 5 point Likert scale (ranging from strongly disagree to 
strongly agree) whether they believed this risk factor could cause venous thrombosis or 
not. The scale consisted of the following items: pregnancy or child birth, birth control 
pills, bed rest, lack of exercise, sitting for long periods, surgery, aging, accident or injury. 
To calculate a score for the knowledge about risk factors for venous thrombosis, we as-
signed one point to each item that participant agreed or strongly agreed with, and points 
were added (possible score range 0-8). 
 
Group 1: Participants who had not been tested before, and group 2: Protein C deficient participants  
 
Attitudes about testing: To assess the attitudes about getting a genetic test for protein C de-
ficiency in both family members that have been tested positive for protein C deficiency 
and family members that had not been tested before, attitude scales were adapted from a 
study by Cameron and colleagues, in which the same attitude scales were being applied to 
assess beliefs about testing for breast cancer susceptibility (20). Both groups completed a 
similar set of the following items, appropriate to their status. For group 2, items referred 
to how individuals felt about the genetic test result now, rather than how they felt when 
they had just received the results.  
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 Health benefits beliefs were assessed with a set of five items (e.g. Knowing 
whether I have protein C deficiency or not would give me more control over my health; 
Knowing that I have protein C deficiency gave me more control over my health). These 
items were all rated on a Likert-scale ranging from 0 (strongly disagree) to 6 (strongly agree) 
and summed to generate health benefits beliefs scores. 
 Psychological benefits beliefs were assessed with four items (e.g. The test would 
reduce the anxiety of not knowing one’s genetic background; The test reduced the anxi-
ety of not knowing my genetic background). These items were all rated on a Likert-scale 
ranging from 0 (strongly disagree) to 6 (strongly agree) and summed to generate psychological 
benefits beliefs scores. 
Psychological distress beliefs were assessed with five items (e.g. Knowing that I 
have protein C deficiency would seriously harm my self-image; Knowing that I have pro-
tein C deficiency seriously harmed my self-image). These items were all rated on a Likert-
scale ranging from 0 (strongly disagree) to 6 (strongly agree) and summed to generate psycho-
logical distress beliefs scores. 
 Furthermore, participants who had not been tested before (group 1) filled in two 
items about their interest in getting a genetic test and their beliefs in the likelihood of re-
ceiving a positive test result.  
Testing interest: Interest about getting the genetic test for protein C deficiency was assessed 
with one item: How interested are you in getting a genetic test for protein C deficiency? 
This item was rated on a 7 point Likert-scale ranging from 1 (not at all interested) to 7 (ex-
tremely interested). 
Likelihood of having protein C deficiency: With one item, the belief in the likelihood of receiv-
ing a positive test result was assessed: If you would be tested, how likely do you think it is 
that you have protein C deficiency? This item was rated on a 7 point Likert-scale ranging 
from 1 (not at all) to 7 (almost certain). 
 
Group 3: Participants without protein C deficiency 
 
Three additional items were added for participants who tested negative for protein C de-
ficiency. All items were rated on a 7 point Likert-scale ranging from 1 (not at all) to 7 (ex-
tremely). 
Relief: One item assessed the amount of relief the participants felt after finding out they 
did not have protein C deficiency: Did you feel relieved after finding out you do not have 
protein C deficiency?  
Guilt: One item assessed whether participants felt guilty about not having protein C defi-
ciency: If other people in your family have protein C deficiency, did you feel guilty after 
finding out you do not have it?  
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Likelihood of having protein C deficiency if tested again: One item assessed the false or correct 
beliefs of participants about the likelihood of getting a positive test result if they would 
be tested again: If you would be tested again, how likely do you think it is that you  
 A further 6 questionnaires were removed because of incomplete data. The re-
maining database consisted of 168 participants. The mean age of the participants was 
44.4 (SD 14.2) years with a range from 18 to 76 years. The sample consisted of 73 men 
(43%) and 95 women (57%). Of all participants 92 subjects (55%) had been tested for 
protein C deficiency in a previous study (18), and 76 subjects (45%) had not been tested 
before and thus did not know their status when they completed the questionnaires. Of 
the tested participants, 34 people had protein C deficiency, and 58 participants had tested 
negative.  
A total of 265 family members were invited to participate in the study. Of the non-
responders, 30 (11.3%) refused to participate, 22 (8.3%) did not show up at their sched-
uled appointment, and 15 (5.7%) could not participate due to other reasons such as ill-
ness. A questionnaire was eventually filled out by 198 (74.7%) family members. Ques-
tionnaires of 24 participants who had already suffered from venous thrombosis were re-
moved from the present analyses because the aim of this paper was to study attitudes 







have protein C deficiency?  



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In further analyses, a distinction was made between the three groups of participants: par-
ticipants who had not been tested (group 1), participants with protein C deficiency, and 
participants without protein C deficiency. Internal consistency of all attitudes scales was 
satisfactory (Cronbach’s alpha’s > .70) and the items that form the risk perception and 
worry scores were highly correlated (r = .90 and r = .87). To test for age differences, a 
median split of the sample was made (median = 45). To protect against inflation of type 
1 error from multiple correlations and other statistical tests we used p < 0.01 as our criti-
cal value for all statistical tests. 
 
Group 1: Participants who had not been tested before (n = 76) 
 
Table 1 presents means, standard deviations and intercorrelations among all measures, 
for participants that had not been tested for protein C deficiency. Means for risk percep-
tion and thrombosis-related worry were 3.9 and 3.4 on scales ranging from 2-14, indicat-
ing that participants did not think it is very likely that they would ever get venous throm-
bosis or worry a lot about it.  Mean scores on beliefs in the health benefits and psycho-
logical benefits of testing were 20.6 and 15.1 on scales ranging from 0-30 and 0-24, 
whereas the belief in psychological distress following the genetic test was 7.5 on a scale 
ranging from 0-30. This indicates that beliefs about the positive consequences of getting 
a genetic test were stronger than beliefs about the negative consequences of the test. For 
the benefits of testing, the item with the highest mean scores was ‘I should get tested for 
the sake of my family and loved ones’ (mean 4.7), indicating that deciding to have a ge-
netic test for protein C deficiency is primarily a matter of concern for the family. The 
item with the lowest mean score was ‘The test results would help me in making decisions 
about whether and when to have children’ (mean 0.7). The mean score on the trait form 
of the STAI was 36.3 (SD 9.6). Participants were quite interested in getting a genetic test 
for protein C deficiency (mean 4.6 on a scale ranging from 1-7) and did not think it was 
very likely that they would have protein C deficiency (mean 2.6 on a scale from 1-7). Risk 
perception and worry were correlated (r = .51, p < 0.01). Higher trait anxiety was related 
to a higher belief in psychological distress following the test (r = .37, p < 0.01), but not 
to a higher interest in getting the test, or a higher belief that one will have protein C defi-
ciency. Beliefs in higher health and psychological benefits of testing were correlated with 
more interest in getting the genetic test (r = .59 and .46, p < 0.01) and a belief that one 
will have protein C deficiency (r =.35 and .41, p < 0.01). Older participants had higher 
scores on thrombosis-related worry than younger participants (p < 0.01). No sex differ-
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Group 2: Participants with protein C deficiency (n = 34) 
 
Table 2 presents means, standard deviations and intercorrelations among all measures, 
for participants who previously have been tested positive for protein C deficiency. Risk 
perception and thrombosis-related worry were higher than risk perception and worry 
scores for participants who had not been tested (means 5.4 and 5.5 on scales ranging 
from 2-14). Beliefs in the health benefits, psychological benefits and psychological dis-
tress following the test were marginally lower than the beliefs of participants who had 
not been tested (means 19.4 and 14.3 and 5.3 on scales ranging from 0-30, 0-24 and 0-
30). For the health and psychological benefits of testing, the item with the highest mean 
score was again ‘I got tested for the sake of my family and loved ones’ (mean 4.6 on a 
scale ranging from 1 to 7). Furthermore, the item with the lowest mean score was again 
‘The test results helped me in making decisions about whether and when to have chil-
dren’ (mean 1.6 on a scale ranging from 1-7). The mean score on the trait form of the 
STAI was 32.9 (SD 9.0). Risk perception and worry were correlated (r = .70, p < 0.01). 
Beliefs in health benefits and psychological benefits following the genetic test, were also 
related (r = .60, p < 0.01). Both thrombosis-related worry and trait anxiety were corre-
lated with psychological distress following the genetic test (r = .52 and r = .61, p < 0.01). 
There were no sex or age differences for any of the measures.  
 
Group 3: Participants without protein C deficiency (n = 58) 
 
Table 3 presents intercorrelations among all measures, means and standard deviations, 
for patients who had been tested negative for protein C deficiency. In this group, risk 
perception and thrombosis-related worry were lower than in the other groups and corre-
lated as well (means 3.2 and 3.2 on scales ranging from 2-14, r = .62, p < 0.01). The 
mean score on the trait from of the STAI was 32.5 (SD 9.4). More than half of the par-
ticipants (61%) reported that they felt relieved after finding out that they did not have 
protein C deficiency and the majority (81%) did not feel guilty when other family mem-
bers were tested positive. Furthermore, most participants (87%) correctly assumed that a 
second test would still be negative. A higher risk perception or worry about getting 
thrombosis was associated with a higher belief that a second test would give a positive 
result (r = .33 and .28), but these results did not reach statistical difference. There were 




T-tests and ANOVAs with Scheffé's post hoc tests were used to test for differences be-
tween the three groups on the various measures. Scores for risk perception and worry 
were found to be significantly higher (ANOVA:  F = 9.4, p < 0.001  and F = 15.8,  p < 
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0.001) for the group with protein C deficiency compared to the group without protein C 
deficiency and those who had not been tested before (see Figs. 1 and 2). Surprisingly, 
scores on the trait form of the STAI scores were highest for the group who did not know 
their protein C status (See Figure 3), but this effect did not reach statistical significance 
(ANOVA: F = 3.2, p = 0.45). 
 T-tests demonstrate that for attitudes about genetic testing, individuals who had 
not been tested and individuals with known protein C deficiency did not differ signifi-
cantly on any of the measures of psychological distress, psychological benefits and health 
benefits of receiving a genetic test result. 
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Legend Figure 1, 2, and 3: 
Group 1: Participants who had not been tested before 
Group 2: Participants with protein C deficiency  
Group 3: Participants without protein C deficiency  
 
 
Knowledge about other risk factors for venous thrombosis 
 
The risk factors that were believed to be most likely to cause venous thrombosis by the 
participants in our sample were lack of exercise (50% agreed or strongly agreed with the 
risk factor), aging (49% agreed or strongly agreed with the risk factor) and surgery (45% 
agreed or strongly agreed with the risk factor). No differences could be detected between 
the three groups or for younger and older participants. Women were more likely than 
men to agree with the risk factor birth control pills (t = -4.53, p < 0.001). 
 To assess whether knowledge about the risk factors for venous thrombosis was 
related to perceptions of risk, thrombosis-related worry and attitudes about genetic test-
ing, we calculated correlations between the total knowledge scores and the other meas-
ures. The only significant correlation was found in the group that had not been tested 








The results of this family study indicate that asymptomatic individuals with a family his-
tory of venous thrombosis perceive the psychological and health benefits of getting a ge-
netic test for protein C deficiency as higher than the psychological distress following the 
test. Interestingly, it seems that attitudes about getting the genetic test did not differ sig-
nificantly between the group with protein C deficiency and the group that had not yet 
been tested. This indicates that the expectations of the participants about getting the ge-
netic test were realistic in terms of their expectations about the potential health and psy-
chosocial benefits of testing as well as the psychological distress a positive test result 
might cause. However, it is possible that significant differences could not be detected 
because of the relatively small number of participants in each group. Furthermore, since 
participants were not recently tested, it is possible that adverse psychological effects have 
arisen directly after receiving the test result but that individuals have adapted to their 
condition over the years, by giving the psychological effects of their condition a different 
meaning. This effect, which has been applied to some extent in quality of life research, is 
called response shift (21;22). Therefore, these results should be taken with some caution. 
 For participants who had been tested positive for protein C deficiency, trait anxi-
ety was highly correlated to psychological distress following the genetic test. As the same 
relationship can be noted for participants who had not been tested before, it seems that 
in general there are few adverse psychological effects of receiving a positive test result for 
protein C deficiency, but that certain vulnerable individuals, with a high predisposition to 
anxiety, might experience considerable distress following the positive test result. This is 
in line with the findings of Lindqvist and colleagues (12), who found that most APC re-
sistant women reported that their lives were unaffected by the knowledge of being APC 
resistant, but that about a quarter of the women became more worried after getting the 
test. Additionally, this effect has been found in earlier research on predictive genetic test-
ing (11). In this light it is also notable that a high score on trait anxiety does not predict 
interest in getting the genetic test or a higher belief in having protein C deficiency among 
the individuals who have not been tested before. This suggests that a high dispositional 
anxiety does not necessarily motivate one to have a genetic test performed or to believe 
they have a high likelihood of having an abnormal result. It is interesting to note that 
worry rather than risk perception was the only measure that correlates with the attitudes 
about the genetic test and interest in getting the genetic test. These findings are consis-
tent with earlier research by Cameron and colleagues (20) and suggest that it is not the 
perception of risk that motivates people to take a genetic test, but the disease-specific 
worry people experience. Since the lifetime risk for venous thrombosis in protein C defi-
cient individuals is 50%, even the protein C deficient participants in this study slightly 
underestimate their risk for venous thrombosis. These relatively low risk perceptions 
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could be due to people’s tendency to underestimate their own risk, also called ‘optimistic 
bias’ (23). 
 Another interesting finding is that knowledge of risk factors for venous throm-
bosis does not differ between the three groups. However, only for the group that has not 
been tested, knowledge about the other risk factors for venous thrombosis is related to 
worry about venous thrombosis. This indicates that without knowing whether one has 
protein C deficiency or not, knowledge of other risk factors for venous thrombosis in-
creases worry and that this knowledge does not influence worry in participants who have 
already been tested.  
 This study describes the results for the asymptomatic family members of one kin-
dred only. It is possible that patients who have experienced an episode of venous throm-
bosis might react differently to getting a positive test result for protein C deficiency or 
another form of thrombophilia. Protein C deficiency is a disorder characterized by a ten-
fold increased risk of developing venous thrombosis and many family members have ex-
perienced the episodes of venous thrombosis in a close relative. This likely explains the 
fact that many family members consider getting tested as very important for their family. 
Patients with a different family history of venous thrombosis may express different emo-
tional reactions to the knowledge of having thrombophilia.  This study was not random-
ized, so there is a possibility that participants who decided to get tested differed from the 
other participants. In addition, because this is a family study in which most of the partici-
pants had already been tested previously (mostly around 10 years ago for the benefits of 
an earlier study), it was not possible to assess the reactions to the test, directly after re-
ceiving the test result. As discussed earlier, it is possible that adverse psychological effects 
have arisen directly after receiving the test result but that individuals have adapted to 
their condition over the years due a response shift. This effect has been noted in earlier 
research on hereditary cancer as well (9;24), and should be acknowledged in further re-
search on the psychological consequences of genetic testing for thrombophilia. 
 Taking the limitations of this study and their possible effect on the outcome of 
this study into account, we can conclude by saying that there do not seem to be many 
long-term negative psychological consequences of genetic testing for thrombophilia as 
measured by thrombosis-related worry and psychological distress following the test re-
sults. However, the short-term effects of testing deserve more attention in future studies. 
Future studies should investigate a more diverse group of thrombophilia patients with 
variation in risk factors. Ideally such a study would have a randomized longitudinal de-
sign, with measurements of psychological distress immediately after receiving the test 
result and at a specified later time point, to investigate whether the duration and intensity 
of the perceived emotional impact of the test changes over time. In addition, it would be 
useful to include measures about state anxiety or depression following the genetic test 
result. From a clinical perspective, this study indicates that genetic testing for protein C 
deficiency does not have many adverse psychological effects in the long term. However, 
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it is also important to note non-tested individuals from a high-risk family do not worry 
excessively about developing venous thrombosis. To make a fully informed choice about 
genetic testing for thrombophilia, it is important that physicians inform patients in great 
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This study applied the Common-Sense Model (CSM) to predict risk perception and dis-
ease-related worry in 174 individuals with a genetic predisposition to venous thrombosis 
(thrombophilia). Participants completed an adapted version of the Illness Perception 
Questionnaire-revised (IPQ-R) and measures assessing risk perception and worry. Re-
gression analyses revealed that illness perceptions were only modest predictors of risk 
perception but better predictors of worry, suggesting that illness perceptions are more 
linked with affect after genetic screening rather than cognitive appraisals of disease risk. 
Further research should refine the IPQ-R in populations at risk of a disease and examine 
the value of the CSM in explaining the relationship between risk perception, worry, and 





Perceived risk of disease is the expectancy of an individual of getting a specific disease at 
some point in his or her life, and its role as a determinant of health behavior is well es-
tablished. In the area of cancer screening, risk perceptions have been found to be posi-
tively associated with screening intentions and protective behavior such as breast self-
examinations (1;2). Inaccurate perceptions of risk are commonly held by individuals at 
risk of a disease, and they tend to persist even after genetic counseling (3). These inaccu-
rate perceptions of disease risk could have a negative effect on well-being and preventive 
behavior. A growing body of research indicates that disease-related worry also plays a 
motivational role in promoting health behavior, and that its associations with behavior 
are sometimes even stronger than the associations of risk perception (4-7). Although risk 
perception and disease-related worry tend to be correlated (4), it appears that they can 
have distinctive influences on health behavior.  
Relatively little research has examined how individuals formulate their appraisals 
of disease risk and what factors influence their disease-related worry. Perceptions of 
health risk are fundamentally based on perceptions of the target illness, and so our un-
derstanding of the construction of risk perceptions can be informed by the theoretical 
understanding of illness representations. In this light, the Common-Sense Model of ill-
ness representation and self-regulation (CSM) can be useful in understanding risk percep-
tions and worry about disease in individuals at a genetic risk for a disease (8-11). The 
CSM can provide a theoretical framework in understanding the meaning of risk by focus-
ing on the health threat that individuals perceive they are at risk of experiencing (12;13).  
The model describes a system with two parallel pathways of self-regulatory processes that 
operate when a patient confronts a health threat. Components of the first pathway in-
clude the cognitive representation of an illness, which includes five representational at-
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tributes: the label and symptoms that individuals associate with the illness (identity), be-
liefs about the etiology (cause), expected outcomes (consequences), beliefs about the du-
ration (timeline) and the expected controllability (cure/control) of the illness (11;14). The 
second pathway of the model involves the regulation of emotional reactions to a health 
threat, such as worry and distress; these emotions are shaped by the representational at-
tributes. Perceived risk and worry about health threats are reflected in these two path-
ways, respectively. The information represented in each of the domains of illness repre-
sentations may influence perceptions of disease risk and worry about the disease (12).  
The CSM has been applied primarily in studies aimed at understanding psycho-
logical responses in patients who are physically ill. Studies investigating the influence of 
illness perceptions on outcome in patients with a chronic illness have provided support 
for the hypothesis that a strong illness identity (the attribution of many symptoms to an 
illness), as well as beliefs in a long duration and serious consequences have a negative ef-
fect on the well being of patients (15;16). Yet it is likely that illness perceptions are also 
important predictors of responses to health threats in healthy individuals, such as those 
with a genetic predisposition to an illness (17). In families with a history of a certain dis-
ease, it is likely that genetically predisposed but asymptomatic family members have wit-
nessed episodes of the disease in their close relatives. These experiences, together with 
the information received from medical caregivers and gathered by themselves (e.g., 
through the Internet), may provide the basis for perceptions about the disease which, in 
turn, guide their risk perceptions and worry about this health threat.  
Only few empirical studies have applied the CSM to study the impact of illness 
perceptions in a population at an increased risk of a disease. A study by Rees and col-
leagues, assessed the relationship between illness perceptions and distress in women at an 
increased risk of breast cancer and found a modest relationship between cancer worry 
and the subscales assessing identity, acute/chronic timeline, and consequences beliefs 
(18). Kelly and colleagues used the Common-Sense Model in a qualitative study to under-
stand cancer risk perceptions in individuals testing for BRCA1/2 mutations (19). The 
findings suggested that individuals based their risk perceptions on beliefs regarding the 
causes of cancer (such as a family history of breast cancer), control or cure of cancer 
through health behaviors or surgery, and the timeline for developing cancer. In this pa-
per, we used the CSM as the theoretical framework for an assessment of risk perceptions 
and thrombosis-related worry in a population of individuals with a genetic predisposition 
to venous thrombosis. This population has received little attention in research on risk 
perceptions and genetic testing.  
In the past several years, several genetic factors that predispose to venous throm-
bosis have been identified (20-23). Venous thrombosis is a multi-causal disease that is 
characterized by the formation of a blood clot (thrombus) in a vein, which blocks the 
blood flow from the affected body part. Symptoms of a venous thrombosis in the deep 
veins of the legs include pain, swelling, redness and tenderness of the skin. The major 
 101
Chapter 6 Using the CSM to predict risk perception and worry 
 
complication, pulmonary embolism, which may be life-threatening, happens when a part 
of the clot embolises to the lungs. Chronic impairment of the venous outflow of the leg, 
the postthrombotic syndrome, may cause severe disability. The annual incidence of diag-
nosed venous thrombosis, including pulmonary embolism, is 1-3 in 1000 individuals (24). 
Quality of life in individuals with venous thrombosis is impaired relative to that of the 
general population, especially in the presence of the postthrombotic syndrome. This im-
pairment encompasses physical, social and psychological domains of quality of life (25-
27).  
Thrombophilia is an increased tendency to develop venous thrombosis, often 
due to a genetic defect. Among the genetic risk factors that have been discovered so far 
are factor V Leiden, protein C, protein S, and antithrombin deficiency (20-23;28). Indi-
viduals from families with inherited thrombophilia have a 10-20 times increased risk of 
venous thrombosis compared with a normal population (relative risk 15.7, 95% CI 9.2-
26.8) (29). A combination of defects is associated with the greatest risk of venous throm-
bosis. For the single defects, the lowest risk is associated with Factor V Leiden and the 
highest risk with antithrombin deficiency (29-31). Although it is possible to treat indi-
viduals at a risk of venous thrombosis with prophylactic anticoagulant treatment, this 
treatment itself encompasses a risk of complications such as bleeding (32;33). Therefore, 
debate continues about whether widespread thrombophilia testing is beneficial in terms 
of improved prevention and management of thrombosis, as the benefit of treatment 
should be weighed against the risk of severe haemorrhage (34;35). Individuals with 
thrombophilia face uncertainty regarding if and when venous thrombosis will develop, 
and if and how they can prevent this.  
Literature about the possible emotional consequences of genetic testing for 
thrombophilia is scarce and emotional consequences have not been taken into account in 
the debate on the usefulness of thrombophilia screening. As in similar conditions such as 
hypercholesterolemia, it is important to pay attention to the psychological impact of test-
ing for thrombophilia (36). To our knowledge only three publications have evaluated the 
social and psychological impact of awareness of carriership of thrombophilia (37-39). 
These studies indicated that individuals who tested positive for thrombophilia were faced 
with increased worry about developing thrombosis, stigmatization, and problems with 
insurance eligibility.  
The primary objectives of the current study were to examine the representations 
of venous thrombosis developed by thrombophilic individuals, and to assess the associa-
tions of these representations with perceptions of the likelihood of getting thrombosis 
and thrombosis worry. We predicted that past experience of venous thrombosis would 
be associated with perceptions of greater likelihood of experiencing venous thrombosis 
in the future. Furthermore, it was predicted that older individuals without a personal his-
tory of venous thrombosis would perceive venous thrombosis to be less likely than 
younger individuals, based on the reasoning that if it was likely to occur, then they would 
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have experienced it by this point in their lives. Both of these associations would suggest 
‘logical’ appraisals of perceived likelihood. Yet likelihood perceptions can also be influ-
enced by ‘nonrational’ influences. Specifically, we expect that the more one has strong 
consequences beliefs (which are more likely than weak consequence beliefs to involve 
vivid, graphic, easily imagined scenarios of suffering) and high coherence beliefs (i.e., a 
clear, developed, coherent representation of the illness), the greater the perceived likeli-
hood of venous thrombosis. These effects would reflect the use of the availability and 
simulation heuristics (40;41). Thus, we hypothesized that ‘consequences’ and ‘coherence’ 
beliefs would have strong associations with risk perception. Furthermore, theoretically, 
all of the IPQ-R subscales should be associated with disease-related worry for people 
who know they are at a genetic risk for a disease (12). In line with the findings of Rees et 
al. (18), we expect that participants with strong ‘identity’ and ‘consequences’ beliefs 
(those who perceive venous thrombosis as having more symptoms and more serious 





Participants and procedure 
 
Participants in this study were adult thrombophilic individuals who were enrolled in the 
European Cohort on Thrombophilia (EPCOT) study in the Netherlands between 1994 
and 1997 and followed until 2001 (42;43). Included were all registered probands (first of 
a family in whom thrombophilia was detected) with a deficiency of antithrombin, protein 
C, protein S or factor V Leiden, and their registered relatives with thrombophilia. Partici-
pants in this study had to be over 18 years old and capable of completing a questionnaire. 
Data were collected in 2004 by mailed questionnaires. Non-responders received a re-
minder questionnaire about 2 months after the initial questionnaires were sent out. All 
participants signed an informed consent form to use previously collected medical data 




Demographic and illness related variables. Demographic and illness-related variables of all par-
ticipants were collected and included age, gender, thrombosis history (dates, location of 
the thrombosis), and details about the type of thrombophilia (protein C deficiency, pro-
tein S deficiency, antithrombin deficiency, Factor V Leiden or a combination of Factor V 
Leiden and other defects).  
Illness perceptions. To measure illness perceptions, the revised version of the Illness Percep-
tion Questionnaire (IPQ-R) was used, which is a measure based on the CSM (44). The 
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original Illness Perception Questionnaire (IPQ) was designed to assess the five attributes 
of illness representations: identity, timeline, consequences, control and cause (45). In the 
revised version, a subscale was added to assess emotional representations, such as anxiety 
and anger, generated by an illness. The IPQ-R also incorporates a subscale called ‘illness 
coherence’. This subscale was added to assess the extent to which the illness makes sense 
to the patient. Furthermore, it includes a measure of how much one believes an illness 
fluctuates or comes and goes over time (‘cyclical timeline’), and it has separated the 
‘cure/control’ subscale into ‘personal control’ and ‘treatment control’ subscales. 
 The questionnaire was adapted for use in a population with thrombophilia so that 
both participants with a history of thrombosis and participants without a history of throm-
bosis could complete the same set of questions. The identity scale consisted of 14 general 
symptoms and asked participants to state whether they believe this symptom is related to 
venous thrombosis; scores reflect the number of illness-related symptoms. The items for 
the acute/chronic timeline, cyclical timeline, consequences, personal control, treatment 
control, illness coherence and emotional representations subscales were rated on a 5-
point Likert type scale ranging from strongly disagree to strongly agree. All items were adapted 
for use in a population that is genetically predisposed to venous thrombosis, but does not 
necessarily have a personal experience with the illness. For instance ‘My illness will last a 
short time’ was replaced by ‘Venous thrombosis lasts a short time’. The total number of 
items in this section is 37. Scores were the mean rating for each subscale. The last section 
presented the causal dimension, consisting of 24 items rated on the same 5-point Likert 
scale ranging from strongly disagree to strongly agree. Six causes that are specific risk factors 
for venous thrombosis (such as the use of the oral contraceptives and prolonged bed-
rest) were added to the original 18 causes from the IPQ-R. An open-ended question 
asked individuals to list any other causes that are important to them.  
Risk perception. Perceived risk of venous thrombosis was assessed with two items that 
were adapted from Cameron & Diefenbach (4) (r=.74): 1. How likely do you think it is 
that, at some point in your life, you will get thrombosis? 2. How vulnerable do you think 
you are to getting thrombosis at some point in your life? Each item was rated on a 7 
point Likert scale ranging from 1 (not at all) to 7 (almost certain or extremely). To calculate a 
score for risk perception, ratings on both items were added (range 2-14).  
Thrombosis worry. Worry about venous thrombosis was assessed with two items (r=.90) (4): 
1. To what extent are you worried about getting thrombosis? 2. To what extent are you 
concerned about getting thrombosis? Each item was rated on a 7 point Likert scale rang-
ing from 1 (not at all) to 7 (extremely). These ratings were summed to generate a thrombo-










All data were entered and analyzed using SPSS 11.5. Means and standard deviations were 
calculated for all measures. Internal consistency of the subscales of the IPQ-R was estab-
lished by calculating Cronbach’s alpha coefficients. To compare differences in scores be-
tween participants with and without a history of venous thrombosis, t tests and 95% con-
fidence intervals were used. To detect differences in scores between participants with 
different types of thrombophilia analyses of covariance (ANCOVA) were used. Pearson 
correlations were calculated to detect relationships between the subscales of the IPQ-R, 
thrombosis worry and perceived risk. To assess the independent associations of the ill-
ness perceptions with perceived risk and thrombosis worry scores, regression analyses 
were performed. In these analyses, demographic and disease-related variables (age, 
thrombosis-history, and type of thrombophilia) were entered in step 1 and illness percep-







Questionnaires were sent to 251 individuals. A total of 196 out of 251 individuals (78%) 
returned the questionnaire. Twelve questionnaires were incomplete, and were therefore 
not included in the analyses. Furthermore, 10 participants had suffered only from super-
ficial thrombophlebitis. Since this group will potentially have different perceptions of ve-
nous thrombosis, but is too small for quantitative analyses, we removed these partici-
pants from the present analyses. The remaining database consisted of 174 participants, of 
whom 95 (55%) had suffered from venous thrombosis. More than half (52%) of these 
participants had experienced one thrombotic episode, 24% had experienced two episodes 
and another 24% had experienced 3 or more episodes of venous thrombosis. The re-
maining 79 participants (45%) did not have a history of venous thrombosis. The sample 
consisted of 94 women (54%) and 80 men (46%). Ages were between 26 and 87 years of 
age, with a mean of 53 years. Within the sample 62 participants (35.6%) had the factor V 
Leiden mutation, 53 participants (30.5%) had protein C deficiency, 26 participants 
(14.9%) had antithrombin deficiency, 20 participants (11.5%) had protein S deficiency 
and 13 participants (7.5%) had factor V Leiden in combination with one of the other de-
fects.  
 Of the 55 non-responders, 6 individuals had moved house and could not be 
reached, 4 were deceased and 3 were incapable of completing the questionnaire due to 
illness. Non-responders were slightly younger than responders (48 vs. 53 years). Non-
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responders did not differ from responders with respect to gender, type of thrombophilia 




Table 1 presents means and 95% confidence intervals for the means on the subscales of 
the IPQ-R. Intercorrelations between the subscales of the IPQ-R and Cronbach’s alphas 
are depicted in Table 2. The internal consistencies of the acute/chronic timeline, conse-
quences, illness coherence, personal control and emotional representation subscales were 
satisfactory, ranging from .68 to .80. The cyclical timeline subscale originally had a Cron-
bach’s alpha of 0.61. After removing item 31 (‘Venous thrombosis is very unpredictable’), 
the internal consistency improved to .69. The low internal consistency of the treatment 
control subscale (.47) could not be improved by item reduction, so it was decided to 
leave this subscale out the further analyses. 
 
 
Table 1 Means and 95% confidence intervals for means on the subscales of the 






Thrombosis history  
(N= 95) 
No thrombosis history 
(N=79) 
All participants  
(N = 174) 
Identity 4.3 (3.8-4.9) 3.6 (3.1-4.1) 4.0 (3.6-4.4) 
Timeline acute/chronic 3.4 (3.2-3.6) 3.3 (3.1-3.4) 3.3 (3.2-3.5) 
Consequences 3.1 (3.0-3.3) 3.2 (3.0-3.2) 3.1 (3.0-3.2) 
Personal control 3.2 (3.0-3.3) 3.2 (3.1-3.3) 3.2 (3.1-3.3) 
Illness coherence 3.7 (3.5-3.8) 3.3 (3.2-3.5) 3.5 (3.4-3.6) 
Timeline cyclical 2.9 (2.6-2.9) 2.9 (2.7-3.0) 3.0 (2.7-2.9) 
Emotional representa-
tions 
2.6 (2.4-2.7) 2.5 (2.4-2.6) 2.5 (2.4-2.6) 
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On the identity subscale, participants attributed a mean of 4.0 symptoms to venous 
thrombosis. The symptoms that were mentioned most often were pain (87% of individu-
als reported that this symptom was associated with venous thrombosis), fatigue (65%), 
breathlessness (51%), and loss of strength (43%).  A series of t tests was used to detect 
differences in illness perceptions between participants with and without a history of ve-
nous thrombosis. No differences on the subscale identity were detected between partici-
pants with and without a history of venous thrombosis. On the other subscales, a signifi-
cant difference between individuals with and without a history of venous thrombosis 
could be detected only on the illness coherence subscale (mean 3.7 vs. 3.3, p < 0.01, 95% 
CI of the difference (0.1, 0.6)). This suggests that individuals who have a personal experi-
ence with venous thrombosis feel they have a better understanding of the disease. 
 In terms of perceived causes of venous thrombosis, the causes that were reported 
most often (the ones with the greatest proportions of participants who agreed or strongly 
agreed) were heredity (96%), immobilization (92%), surgery (90%), bed rest (85%), and 
lack of exercise (84%). On the open-ended question, the most frequent answers fell into 
the categories of heredity (67%), immobilization (59%), and surgery/accident (40%). 
Analysis of covariance revealed that differences between groups with different 
types of thrombophilia could be detected only on the subscale personal control,  after 
controlling for thrombosis history (F(5,174) = 2.96, p < 0.05), which was due to a differ-
ences in scores of participants with antithrombin deficiency and factor V Leiden. 
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Thrombosis worry and risk perception 
  
T-tests revealed that participants with a history of venous thrombosis had a significantly 
higher perception of their risk of getting venous thrombosis again (10.6 vs. 8.1, p < .001, 
95% CI of the difference (1.6, 3.4)), and were significantly more worried about getting 
venous thrombosis again (8.0 vs. 6.2, p< .01, 95% CI of the difference (0.8, 2.9)) than 
participants without a history of venous thrombosis. Analyses of covariance revealed 
that, after controlling for age, thrombosis history was still a significant predictor of risk 
perception and worry scores (risk perception: F(2,168) = 33.64, p < 0.001, 95% CI of the 
difference (1.6, 3.4); worry: F(2,168) = 11,41, p < 0.001, 95% CI of the difference (0.8, 
2.9)). 
Risk perception and worry scores for the different types of thrombophilia are de-
picted in Figures 1 and 2. As can been seen in these figures, participants with antithrom-
bin deficiency had higher scores on both perceived risk and thrombosis worry. Analyses 
of covariance revealed that, after controlling for the effect of thrombosis history and age, 
type of thrombophilia was still a significant predictor of perceived risk; F (4,168) = 2.78, 
p < 0.05. Scheffé’s post-hoc tests revealed that this effect was mainly due to a difference 
in mean scores between antithrombin deficiency and Factor V Leiden. Scores for worry 
did not differ significantly between the different types of thrombophilia; F(4,168) = 0.55, 
p = .70.  
 
Figure 1: Mean scores and 95% confidence intervals for means on risk perception 
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Figure 2: Mean scores and 95% confidence intervals for means on thrombosis 



















Associations between illness perceptions, perceived risk, and thrombosis worry 
 
Table 2 shows correlations between the illness perceptions, perceived risk, and thrombo-
sis worry scores. The attribution of more symptoms to venous thrombosis was related to 
a belief in a longer timeline, more serious consequences, a stronger belief in a cyclical 
timeline, stronger emotional representations and a less coherent understanding of the 
disease. A belief in a longer duration was related to a stronger belief that the illness 
comes and goes over time. A belief in more serious consequences of venous thrombosis 
was related to a less coherent understanding of the disease, a stronger belief in a cyclical 
timeline and stronger emotional representations. A more coherent understanding of ve-
nous thrombosis was related to weaker emotional representations and a weaker belief in 
the cyclical timeline of venous thrombosis.  
Perceived risk was positively related to illness identity and illness coherence. 
Thrombosis worry was also related to the attribution of more symptoms to venous 
thrombosis, as well as a belief in more serious consequences, a less coherent understand-
ing of the disease, and stronger emotional representations. Risk perception and worry 








Two-stage regression analyses were performed to assess the independent associations of 
the illness perceptions with perceived risk and thrombosis worry (see Table 3). Because 
the emotional representations subscale was highly correlated with thrombosis worry, it 
was decided to leave this subscale out of the regression analysis to avoid colinearity.  
Results of the regression analysis of perceived risk revealed that the demographic 
and illness-related variables explained 19% of variance, whereas the illness perceptions 
explained 5%. The full model was significant, p < 0.001. Both younger age and a positive 
history of venous thrombosis were strong predictors of perceived risk scores. The IPQ-R 
subscale that contributed most to the regression equation was illness coherence . 
For thrombosis worry, demographic and illness-related variables accounted for 
7% of the variance whereas the illness perceptions explained 12% of the variance. The 
significance of the total model was p < 0.001. Of the demographic and illness-related 
variables, only a history of venous thrombosis contributed significantly to the regression 
equation. Beliefs in more symptoms and more serious consequences of venous thrombo-
sis were the most important predictors of thrombosis worry. 
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Table 3. Two-stage regression analyses testing the value of the illness perceptions 
in predicting risk perception and thrombosis worry 
Note: The IPQ-R dimension emotional representations was not entered into the regres-
sion analysis for thrombosis-related worry because of a high correlation with thrombosis-
related worry, * p < 0.05, ** p < 0.01, *** p < 0.001 
Regression coefficients 
Dependent variable Predictors Unstandardized  




Step 1  
Age 
Type of thrombophilia 
Thrombosis history 
 
∆R2 = 19 
F = 12.64*** 
 
-.04 ( -.08, -.01) 
-.08 (-.42, .25) 






















∆R2 = .05 
F = 4.78*** 
 
.09 (-.11, .29) 
.27 (-.29, .83) 
.42 (-.42, 1.26) 
-.15 (-.89, .59) 
.73 (-.03, 1.49) 
-.05 (-.78, .67) 



















Step 1  
Age 
Type of thrombophilia 
Thrombosis history 
 
∆R2 = .07 
F = 4.10** 
 
-.01 (-.05, .03) 
.10 (-.28, .48) 





















∆R2 = .12 
F = 4.21*** 
 
.22 (.00, .44) 
-.08 (-.70, .54) 
1.39 (.54, 2.24) 
-.27 (-1.09, .55) 
-.36 (-1.15, .43) 























In this study, the Common-Sense Model (CSM) was used to explore the nature of the 
cognitive representations of venous thrombosis formed by thrombophilic individuals, 
and to evaluate how these representations are associated with risk perceptions and 
thrombosis worry. Perceived risk and thrombosis worry were found to be significantly 
higher for participants with a history of venous thrombosis than for individuals without a 
history of venous thrombosis. Furthermore, perceived risk and worry scores were higher 
for participants with antithrombin deficiency than for participants with any of the other 
thrombophilias. After controlling for thrombosis history and age, analyses of covariance 
revealed that this group difference in perceived risk was still present. This group differ-
ence reveals realistic perceptions, because individuals with antithrombin deficiency ap-
pear to have the greatest venous thrombotic risk of all the single thrombophilias (30;31). 
This finding indicates that knowledge of thrombophilic individuals about their risk of 
venous thrombosis is generally good. On the other hand, individuals with a combination 
of factor V Leiden and other defects do not have higher perceptions of their thrombotic 
risk than individuals with single defects even though biomedical evidence indicates that 
combined defects pose the greatest thrombotic risk (29).  
Few differences in illness perceptions were identified between individuals with a 
history of venous thrombosis and individuals without a history of venous thrombosis. 
The only statistically significant difference in scores was on the illness coherence sub-
scale. In general, it appears that asymptomatic individuals have realistic expectations 
about the experience of having venous thrombosis. However, despite their realistic be-
liefs about venous thrombosis, they tend to score lower on illness coherence, indicating 
that thrombophilic individuals without a history of venous thrombosis do not feel that 
they have a coherent understanding of the illness. More information about venous 
thrombosis could help to strengthen their knowledge about the illness to make them feel 
more confident in understanding the illness. The causes of venous thrombosis that were 
endorsed most frequently by the participants were heredity, immobilization, and surgery, 
which is in line with the view of venous thrombosis as a multicausal disease that is caused 
by both genetic and environmental risk factors (46). 
We hypothesized that perceived risk would be associated with ‘consequences’ and 
‘illness coherence’ beliefs, as well as with younger age and a history of venous thrombo-
sis. The findings partially support these hypotheses. First, correlational patterns revealed 
that perceived risk was positively associated with illness coherence, but it was not corre-
lated with consequence beliefs. Unexpectedly, perceived risk was associated with higher 
identity scores, indicating that those who associated venous thrombosis with a greater 
number of symptoms tended to have higher risk perceptions. The results of the regres-
sion analyses indicate that illness perceptions only have a modest contribution in ac-
counting for the variance in perceived risk scores, with illness coherence as the only sig-
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nificant predictor. As expected, younger age and a history of venous thrombosis were 
predictors of perceived risk scores. 
We predicted that worry would be associated with all IPQ-R subscales, with the 
strongest associations for the identity and consequences subscales. Worry was indeed 
found to be significantly associated with identity and consequences. Regression analyses 
revealed that illness perceptions could account for a greater amount of variance in 
thrombosis worry scores than risk perception scores Also, as predicted, identity and con-
sequences were both modest but significant predictors of worry. Demographic and ill-
ness-related variables explained only a modest amount of variance in thrombosis worry 
scores with thrombosis history being the only significant predictor. These results indicate 
that the cognitive components of illness representations have a stronger association with 
illness-related affect, rather than with more reasoned, cognitive appraisals of disease risk. 
Other variables, such as a personal history of venous thrombosis, seem to be better pre-
dictors of risk perception.  
This is one of the first studies that uses the Illness Perception Questionnaire-
Revised to assess the illness perceptions of individuals at risk of a disease. The treatment 
control subscale showed a low internal reliability (α = .47) that could not be improved by 
item reduction, and it was therefore removed from subsequent analyses. This might give 
an indication that thrombophilic individuals do not have a clear understanding of the 
treatment of venous thrombosis. Some other subscales showed only moderate internal 
consistency, such as the illness coherence subscale. Rees and colleagues (18) encountered 
similar difficulties regarding the internal consistency of some of the subscales. A further 
issue is that the emotional representations subscale was highly correlated to thrombosis 
worry. Although thrombosis worry reflects persistent concern about developing the dis-
ease and the emotional representations subscale reflects the affective response to venous 
thrombosis, it seems that in the present form, the scales are not differentiated enough 
from each other. Furthermore, the control subscales of the IPQ-R measure control over 
the recovery of venous thrombosis. In populations at risk of a disease, beliefs about con-
trol over the prevention of a disease are probably more relevant. With the original word-
ing of the IPQ-R, it appears to be difficult to capture the illness perceptions of individu-
als at risk of a disease. Further research should aim at refining the subscales so that they 
adequately capture illness perceptions in at-risk populations. The development of a new 
version of the IPQ-R, specifically for individuals ‘at risk’, could be a possible outcome.  
Non-responders were slightly younger than responders in this study, which may 
have biased the results. Since younger people perceived their risk for venous thrombosis 
as higher than did older people, the perceived risk means observed in the present study 
are likely to be somewhat tempered. Another limitation is the cross-sectional nature of 
the study, which precludes definitive interpretations of the directionality of the influences 
among perceived risk, worry, and illness perception components.  
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Further research, preferably with a longitudinal design, and measurements of ill-
ness perceptions, risk perceptions, worry, and health behavior before and after genetic 
counseling, could help to clarify the exact nature of the value of the CSM in explaining 
the regulation of illness risks. A better understanding of the processes involved in how 
individuals form their risk perceptions and worry about a health threat could help clini-
cians in predicting which individuals may exhibit high levels of distress or hold miscon-
ceptions about the magnitude of their risk. These insights also could help to increase un-
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Venous thrombosis is the result of the formation of a blood clot in a vein. It is a com-
mon disease with an incidence of 1-2 in 1000 persons a year. The most common mani-
festation of venous thrombosis is in the veins of the legs and symptoms include pain, 
swelling, redness and tenderness of the skin (1;2). When a piece of the clot breaks off and 
results in pulmonary embolism, it may be fatal (3). Furthermore, patients have up to 50% 
chance of developing chronic problems, i.e., the postthrombotic syndrome (4). In about 
50% of patients with venous thrombosis, a predisposing genetic abnormality can be de-
tected. This predisposition is called thrombophilia (5). Because patients with venous 
thrombosis have to deal with an illness that is possibly fatal, might have serious chronic 
consequences, and might return, it is highly relevant to study the quality of life (QOL) of 
this category of patients. The impact of venous thrombosis on the quality of life of pa-
tients has not gained much attention in the scientific literature. In addition, the possible 
psychological consequences of genetic testing for thrombophilia have only received lim-
ited attention in the scientific literature. This is surprising because research has indicated 
that carriership of a genetic deficit may influence daily life, since it can cause considerable 
distress, especially in vulnerable individuals (6).  
 Research of the Unit of Psychology of the Leiden University Medical Centre, has 
focused on Leventhal’s Common-Sense Model of health and illness behaviour (CSM) (7). 
This model describes a system with two parallel pathways that interact when a patient 
adapts to an illness or health threat and can be useful in explaining outcome, such as 
quality of life, in patients with a chronic illness (7;8). Key elements of this model are the 
illness representations, or illness perceptions. The illness perceptions include five key at-
tributes: the label and symptoms that patients associate with their illness (identity), and 
their beliefs about the etiology (cause), the outcome (consequences), the duration (time-
line) and the controllability (cure/control) of the illness. Research on the Common-Sense 
Model conducted at the Unit of Psychology has resulted in several journal articles on the 
impact of illness perceptions and outcome in patients with a diverse array of illnesses, 
such as Huntington’s disease (9), rheumatoid arthritis, chronic obstructive pulmonary 
disease, psoriasis (10;11), head- and neck cancer (12), and several book chapters (13-15). 
 Because perceptions of health risks such as a genetic risk factor predisposing to 
an illness are also based on perceptions of the target illness, in this case venous thrombo-
sis, it is likely that the Common-Sense Model will prove to be a useful model in explain-
ing outcome in individuals who are at risk of a certain illness (16).  
 Collaboration between the Department of Clinical Epidemiology (LUMC), the 
Unit of Psychology (LUMC) and the Department of Pathology of the University of 
Vermont (VT, USA) resulted in several studies on quality of life in patients with venous 
thrombosis and the psychological impact of thrombophilia testing, of which the results 
are described in this thesis.  
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  The studies described in this thesis had two main aims:  
1) To study the quality of life of patients with venous thrombosis and to examine the role 
of illness perceptions in explaining the quality of life of these patients.  
2) To assess the psychological consequences of genetic testing for thrombophilia, using 
the Common-Sense Model as a theoretical framework. 
 
 
Quality of life in patients with venous thrombosis 
 
The first aim of this thesis, to study the quality of life of patients with venous thrombosis 
and to examine the role of illness perceptions in explaining the quality of life of these pa-
tients, was addressed in chapters 2, 3 and 4.  
  Chapter 2 describes a literature review that aimed to describe studies that as-
sessed quality of life in patients with chronic venous disease. A computer search of the 
Medline database from 1996 to February 2003 was performed to identify relevant papers. 
In addition, the bibliographies of relevant papers were reviewed. Papers were selected if 
they were written in English, French, or German and described the development or use 
of a quality of life instrument in patients with venous disease or treatment of venous dis-
ease. A total of 25 papers were identified, of which only 4 specifically dealt with the as-
sessment of quality of life in patients with venous thrombosis (17-20). One of these stud-
ies used only a disease-specific measure of quality of life (20), whereas the other three 
studies used a combination of disease-specific and generic measures. Main results of 
these four studies indicate that patients with venous thrombosis are impaired in all do-
mains of quality of life. They are impaired in their physical functioning and report pain. 
They have low perceptions of their general health and experience health distress. Im-
pairment of QOL seems to be related to symptom severity and the presence of the post-
thrombotic syndrome. Furthermore, 6 studies examined the effect of different types of 
treatment for venous thrombosis on the quality of life of patients (21-26). The other 
studies reviewed in chapter 2 dealt with quality of life assessment in patients with chronic 
venous insufficiency (5 studies), venous leg ulceration (8 studies), and varicose veins (2 
studies).  
  In the two years since we published our review, the subject of quality of life in 
patients with venous thrombosis has fortunately gained more attention in the scientific 
literature. The group of Kahn and colleagues published a number of studies on this sub-
ject (27-29). To assess quality of life, these studies used both the widely used generic 
measure Short Form-36 (SF-36)(30) and the VEINES-QOL. The VEINES-QOL is a 26-
item disease specific questionnaire that measures venous symptoms, limitations in daily 
activities and psychological disease impact. The major results of these studies indicate 
that on average, QOL is impaired in patients with venous thrombosis compared to a 
general population and improves in the first 4 months following venous thrombosis, but 
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that average QOL remains poorer than population norms. Furthermore, patients with 
the postthrombotic syndrome reported lower quality of life scores than patients without 
the postthrombotic syndrome, especially on the VEINES-QOL. 
 In addition, the subject of quality of life in patients on anticoagulant therapy, 
which is the treatment of choice after venous thrombosis, has also gained more attention. 
Locadia et al. published two papers in which quality of life, health state evaluations, and 
treatment preferences of patients treated with vitamin K antagonists after suffering from 
venous thrombosis were assessed (31;32). Results of these papers indicate that quality of 
life in patients with venous thrombosis was not related to treatment duration and that 
there is substantial variability in health state valuations and treatment preferences in pa-
tients with venous thrombosis. Furthermore, Gadisseur et al. assessed quality of life of 
patients using oral anticoagulants and found that self-management of treatment had a 
positive effect on quality of life versus management by specialized anticoagulation clinics 
(33). 
  In chapter 3, we examined the quality of life of patients with venous thrombosis 
in a well-defined population, using both a generic measure, the SF-36, and a newly devel-
oped disease-specific measure, the VT-QOL. The latter instrument was developed for 
this research and based on interviews held with patients with venous thrombosis and on 
previous quality of life research in this patient population (19;34;35). The VT-QOL as-
sesses quality of life on the dimensions physical functioning, social functioning, general 
mental health, and thrombosis repercussions. The questionnaires were filled out by 45 
individuals who had experienced one or more episodes of venous thrombosis. Although 
the subjects had had their last thrombotic event a median of two years ago, the results of 
this study indicated that an impaired quality of life could still be detected on both meas-
ures. Compared to a general U.S. population sample, the patients in our sample scored 
significantly lower on all subscales of the SF-36, after adjusting the population norms for 
the age and sex distribution in the sample. QOL appeared to be related to self-reported 
symptoms and the presence of the postthrombotic syndrome on both measures. The 
VT-QOL was more sensitive than the SF-36 in detecting differences between patients 
with and without the postthrombotic syndrome. These results are consistent with those 
of Kahn et al., as described above (28;36). We believe that with the VT-QOL, a reliable 
and valid measure to assess quality of life in patients with venous thrombosis has been 
developed, which is more sensitive to the specific problems this group of patients experi-
ences, than general measures such as the SF-36. 
  In this study, the presence of the postthrombotic syndrome was evaluated by 
chart review. The presence of the postthrombotic syndrome was determined by a clini-
cian at different points in time prior to QOL assessment. Ideally, presence of the post-
thrombotic syndrome should be determined at the time of quality of life assessment, by a 
known scale such as the CEAP classification (36;37). However, since the postthrombotic 
syndrome was assessed by the same clinician in every patient, the possibility of inter-rater 
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variability was excluded and possible misclassification was minimized. In addition, we 
found a strong correlation between the classification of the postthrombotic syndrome 
and self-reported symptoms, which suggests that our method for assessing the post-
thrombotic syndrome in this study was still sufficiently reliable. 
  Although the sample size of this study was rather small, we may still conclude 
that venous thrombosis has many negative consequences for the quality of life of pa-
tients. The study described in chapter 3, along with other research in the field, has now 
indicated that even several years after the initial episode of venous thrombosis many pa-
tients still remain impaired in their quality of life because of persisting symptoms, both in 
their daily physical functioning and in their social and psychological functioning. This is 
especially true for patients diagnosed with the postthrombotic syndrome and patients 
who report several symptoms 
 
  
Explaining quality of life in patients with venous thrombosis 
 
As found in chapters 2 and 3, even some years after the initial event, quality of life of pa-
tients with venous thrombosis may remain poorer than that of a general population, es-
pecially in the presence of the postthrombotic syndrome. Since quality of life can not be 
explained by biomedical variables only, and research has shown that the patients’ own 
perceptions play an important role in explaining quality of life, we aimed to assess how 
illness perceptions influence the quality of life of patients with venous thrombosis. The 
results of this study are described in chapter 4. A total of 45 patients with a history of 
venous thrombosis filled out the SF-36 to measure quality of life, and the Illness Percep-
tion Questionnaire-Revised (IPQ-R) (38) to measure illness perceptions. Patients in our 
sample believed that their illness would be prolonged and that their symptoms were not 
cyclical. They mostly attributed their venous thrombosis to bad luck or hereditary factors. 
These attributions are consistent with medical evidence that venous thrombosis is often 
hereditary (39), but also a multicausal disease, often caused by interplay between genetic 
and environmental risk factors, making it hard to pinpoint an exact cause in many pa-
tients (40). A series of regression analyses, in which we controlled for the presence of the 
postthrombotic syndrome and the number of thrombotic episodes experienced by the 
patient, showed that the IPQ-R subscales timeline acute/chronic, personal control, ill-
ness identity and the cause ‘heredity’ were the best predictors of quality of life scores. 
This is in line with earlier research using the original Illness Perception Questionnaire 
and hypotheses derived from the Common-Sense Model, suggesting that individuals who 
perceive their illness as chronic, as having more symptoms, more serious consequences, 
and perceive less control over their illness, will have less adaptive outcomes, such as im-
paired quality of life (41). 
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  The subscales that are new in the revised version of the Illness Perception Ques-
tionnaire, namely illness coherence and emotional representations, did not contribute to 
the regression equations. Especially since patients with the postthrombotic syndrome had 
lower scores on illness coherence as well as on all subscales of the SF-36, the fact that 
illness coherence does not seem to play a role in the explanation of quality of life, is 
noteworthy. In this patient group, having an illness of which patients seem to have a lim-
ited understanding, does not appear to affect their quality of life. Recent studies by Schar-
loo et al.,  and Llewellyn et al., assessing quality of life and illness perceptions in patients 
with head and neck cancer, found that the emotional representations subscale was a good 
predictor of emotional functioning (12;42), so it is interesting that in our study this sub-
scale does not have an effect. 
  Many studies using the IPQ or IPQ-R also incorporate measures of coping, be-
cause one of the premises of the Common-Sense Model is that the relationship between 
illness perceptions and outcome is mediated through coping procedures. However, sev-
eral studies that have attempted to examine this hypothesis in a number of chronic dis-
eases, have failed to find proof for the hypotheses. Those studies found a significant im-
pact of illness perceptions on outcome, with no or only very small additive impacts of 
coping behaviours (10;43;44). Therefore, we chose not to include a measure of coping in 
our study. 
  When we first started this study, the IPQ-R was not adapted for use in a popula-
tion of patients with venous thrombosis. The authors of the original papers in which the 
IPQ and IPQ-R are first described, encourage researchers to adapt the questionnaire to 
their specific patient population and research setting (38;45). In our study, patients at-
tributed only few of the symptoms in the identity subscale to the illness. Many of the 
symptoms in the original subscale are not symptoms that are commonly experienced by 
patients with venous thrombosis. Therefore, in further research symptoms that charac-
terize venous thrombosis, such as swelling, redness and tenderness of skin of the affected 
body part, should be added to this subscale. This would greatly improve the suitability of 
this subscale in patients with venous thrombosis. Furthermore, causes that are specific 
for venous thrombosis should be added to the causal dimension. For instance, known 
risk factors such as the use of oral contraception, pregnancy/childbirth, surgery and im-
mobilization are a few of the possible additions to this subscale (46).  
  Chapter 4 gives an indication that besides the presence of the postthrombotic 
syndrome there are psychological factors that may help to explain quality of life in pa-
tients with venous thrombosis. A belief in a longer duration of venous thrombosis, a 
lower belief in personal control over venous thrombosis, and the attribution of more 
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Psychological implications of genetic testing for thrombophilia 
 
The second aim of the studies described in this thesis was to study the psychological 
consequences of genetic testing for thrombophilia, using the Common-Sense Model as a 
theoretical framework and was addressed in chapters 5 and 6. 
 In chapter 5, the attitudes toward genetic testing for heritable thrombophilia in a 
large family with a high incidence of protein C deficiency were explored. The question-
naire consisted of items about risk perception, thrombosis worry, beliefs in the health 
benefits and psychological benefits of testing, and beliefs in psychological distress after 
testing, derived from research about the consequences of testing for hereditary breast 
cancer genes by Cameron & Diefenbach (47). Furthermore, knowledge about other risk 
factors for venous thrombosis was assessed and all participants filled out the trait form 
of the State-Trait Anxiety Inventory (STAI) as a measure of dispositional anxiety (48). 
Interest in getting a genetic test for protein C deficiency was assessed in participants who 
had not been tested for protein C deficiency before. The questionnaires were filled out 
by a total of 168 participants of whom 76 participants had not been tested for protein C 
deficiency before, 34 participants who had been tested previously and were found to 
have protein C deficiency, and 58 participants who were found not to have protein C de-
ficiency when they had been tested. None of the participants had previously experienced 
venous thrombosis. The main results of this study indicated that the psychological and 
health benefits of testing are perceived as higher than the psychological distress following 
the test by both participants that had not been tested before and participants with protein 
C deficiency. These results are comparable to research on genetic testing in similar condi-
tions, such as familial hypercholesterolemia, which found that learning that one has fa-
milial hypercholesterolemia alters perceptions of control over getting coronary heart dis-
ease, but does not increase anxiety and depression (49). Trait anxiety was related to (a 
belief in) more psychological distress following the test result. Furthermore, it seems that 
increased worry about venous thrombosis was the only variable related to both the atti-
tudes about genetic testing for thrombophilia and genetic testing interest. Perceived risk 
for venous thrombosis was not associated with any of the attitudes measures or with test-
ing interest. This is a notable finding, since perceived risk has been regarded as a key mo-
tivator for health behaviour in a number of theories, such as the health belief model (50) 
and the precaution adoption process (51). In recent years, however, a growing body of 
research has indicated that disease-related worry plays a stronger motivational role in 
promoting health behaviours than perceived risk of disease, and our work supports that 
line of research (52-54). 
 Limitations of this study lie mainly in the fact that it was an cross-sectional family 
study. Participants who had been tested previously, were invited to do so in a previous 
study. Therefore there is a slight possibility for a selection bias. On the other hand, com-
plete randomization in genetic testing studies is complicated because of ethical considera-
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tions. The previous study in which participants had been tested was performed a while 
ago (54) and because of that it was not possible to assess the reactions to the test directly 
after receiving the test result. It is possible that adverse psychological effects have arisen 
directly after receiving the test results but that individuals have adapted to their condition 
over the years. This phenomenon is called response shift and has been noted in earlier 
research on hereditary cancers (55-57). Another possible factor that can bias results in 
this study is the fact that the family members in this study have been involved with medi-
cal research for a number of years. Additionally, they might have witnessed each others’ 
experiences with thrombophilia testing and venous thrombosis and it is likely that they 
have discussed these issues with each other. Therefore, they might be better informed 
and have different perceptions on venous thrombosis and thrombophilia testing than 
individuals who do not have these experiences. 
 Despite these limitations, we believe that the results of the study described in 
chapter 5, that is amongst the first to describe the impact of genetic thrombophilia test-
ing, indicate that in general there are few long-term negative psychological consequences 
of testing for thrombophilia, except in individuals who are vulnerable to high levels of 
anxiety. By most individuals, getting a genetic test is regarded as beneficial for both their 
health and their psychological well-being. 
 
 
Using the Common-Sense Model to predict outcome after genetic testing for 
thrombophilia 
 
In chapter 6 the Common-Sense Model of illness representation (7;8) was applied to 
predict risk perception and worry in individuals with a genetic predisposition to venous 
thrombosis. Participants from the European Cohort on Thrombophilia (EPCOT) (58-
60) filled out a set of questionnaires. An adapted version of the IPQ-R was used to assess 
beliefs of thrombophilic individuals about venous thrombosis. In this version of the 
IPQ-R, the wording of the items was changed to make it applicable to individuals at risk 
of a disease, and some risk factors that are specific to venous thrombosis were added to 
the “causes” subscale. In addition, risk perception and thrombosis worry were assessed. 
A total of 174 participants completed the questionnaire, of whom 95 (55%) had suffered 
from venous thrombosis. We found that individuals with a history of venous thrombosis 
and individuals without a history of venous thrombosis had similar perceptions of the 
disease. Regression analyses revealed that only the IPQ-R subscale illness coherence was 
significantly related to risk perception scores. Young age and a history of venous throm-
bosis appeared to be better predictors of perceived risk of getting venous thrombosis 
than illness perceptions. For thrombosis worry, the subscales consequences and illness 
identity were significant predictors. These results indicate that the cognitive components 
of illness representations have a stronger association with illness-related affect, than with 
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more reasoned, cognitive appraisals of disease risk. Other variables, such as a personal 
history of venous thrombosis, seem to be better predictors of perceived risk than illness 
perceptions.  
  When we compare these results with the only other published quantitative study 
that used the Common-Sense Model as a theoretical framework to assess psychological 
impact of genetic testing, the relationship we found between thrombosis worry and the 
subscales identity and consequences is in line with findings by Rees and colleagues who 
found similar results in a sample of women at increased risk for breast cancer (61).  
  This study was amongst the first that used the Illness Perception Questionnaire-
Revised to describe the illness perceptions of individuals at risk of a disease, which may 
be regarded as both a strength and a limitation of this study. For instance, no associations 
between control beliefs and risk perception or thrombosis worry were identified in our 
study. This was surprising since associations between control beliefs and adaptation to 
illness have been clearly demonstrated in several patient populations (10;62). It is likely 
that beliefs concerning personal control over risk, such as ability to prevent venous 
thrombosis are more important in this population than control over the disease as assessed 
by the IPQ-R.  
  Furthermore, the treatment control subscale showed a low internal reliability (α = 
.47) that could not be improved by item reduction, and it was therefore removed from 
subsequent analyses. Some other subscales showed only moderate internal reliability, 
such as the illness coherence subscale. Rees and colleagues (61) encountered similar diffi-
culties regarding the internal reliability of some of the subscales. A further issue is that 
the subscale emotional representations was highly correlated to thrombosis worry, and it 
was therefore left out of subsequent analyses. With the original wording of the IPQ-R, it 
appears to be difficult to capture the illness perceptions of individuals at risk of a disease.  
  With a closer look at the combined results of chapters 5 and 6 and adopting a 
Common-Sense Model approach, we can note the following: asymptomatic individuals 
from families with a high risk of disease develop representations of the disease through 
information provided by health care providers, family members, and the experiences of 
the disease in family members. This supports the premise of the Common-Sense Model - 
that illness perceptions are derived not only from direct somatic or symptomatic experi-
ence but also from information available in the external social environment (63). A back-
ground from a high-risk family or carriership of a genetic abnormality predisposing to a 
disease is sufficient stimulus to evoke representations of the disease. These illness repre-
sentations, particularly illness identity, perceived consequences and illness coherence, 
have an impact on perceived risk of the target disease and, more strongly and impor-
tantly, on disease-related worry. In turn, disease-related worry has an impact on interest 
in getting a genetic test, and beliefs about the possible distress that may occur after test-
ing. The results reported in this thesis have shown how the Common-Sense Model can 
act as a useful framework to enhance understanding of how psychological factors influ-
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ence psychological response to risk of disease and how this psychological response can 
influence health behaviour. 
 
 
Implications for clinical practice  
 
From the studies described in this thesis it becomes clear that the effects of venous 
thrombosis on the life of patients should not be underestimated. After the initial antico-
agulant treatment of three to six months, symptoms of venous thrombosis are supposed 
to disappear, but our research along with other research in the field has now indicated 
that even several years after the initial episode of venous thrombosis, many patients still 
remain impaired in their quality of life because of persisting symptoms, both in their 
daily, physical functioning, and in their social and psychological functioning. It is impera-
tive that health care providers prove sensitive to the problems patients experience in daily 
life, especially if they are diagnosed with the postthrombotic syndrome. Patients who ex-
perience many difficulties when trying to deal with the negative consequences of their 
illness, could be referred to a health psychologist who could further assist patients in 
adapting to their illness. Furthermore, our research also indicates that not only biomedi-
cal variables contribute to the quality of life of patients with venous thrombosis, but that 
illness perceptions also play a role. Especially beliefs in the duration of the disease, as 
well as beliefs about the self-management of venous thrombosis seem to play an impor-
tant role in the quality of life of these patients. If intervention studies can prove the posi-
tive impact of changing illness perceptions on quality of life in these patients, health care 
providers could aim at addressing perceptions about the duration of their illness and the 
possible management of venous thrombosis, in order to improve quality of life. 
  Confronted with decisions about whether to test patients for thrombophilia or 
not, we may conclude from the results of our study that genetic testing for thrombophilia 
does not seem to have many adverse psychological consequences in the long term. On 
the contrary, many members of high risk families feel that knowing whether they have 
thrombophilia or not will have high health benefits and psychological benefits. We also 
found that for many patients from these families, getting tested is important for the 
benefits of their family and children. However, we should note that most non-tested in-
dividuals from high-risk families do not worry excessively about their risk for venous 
thrombosis, so performing a genetic test in order to reduce worry about venous throm-
bosis is often not necessary. The research described in this thesis has also pinpointed 
some of the psychological factors that should be taken into account when deciding 
whether or not an individual patient is eligible for thrombophilia testing. Our results in-
dicate that certain vulnerable individuals with a high predisposition to anxiety might ex-
perience considerable distress following the (positive) test result. Furthermore, thrombo-
philic individuals who believe that venous thrombosis has many symptoms and who be-
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lieve in serious consequences of the illness, might experience increased thrombosis 
worry. Illness beliefs and disease worry should be explicitly assessed in consultations. Pa-
tients should be able to make a fully informed choice. Clinicians should inform patients 
in great detail about advantages and disadvantages of testing, as well as about the mean-
ing of a positive test result. Furthermore, as Marteau & Croyle suggest, the initial offer of 
a test should be separated in time from the blood sample being taken, to allow patients to 
make a decision. Test results should be explained and support should be offered to tested 





From the studies presented in this thesis we may infer some directions for future re-
search on the topics of quality of life in patients with venous thrombosis and psychologi-
cal impact of genetic testing for thrombophilia. In addition, we can make some recom-
mendations about the direction further research about the Common-Sense Model should 
take.  
  First of all, longitudinal research is needed on illness perceptions in patients with 
venous thrombosis to assure the causal direction of the effects we found in our study, in 
which illness perceptions are measured at baseline and outcome is measured on a subse-
quent occasion. Preferably this research would have a large sample size and a population 
of patients who have recently had their first episode of venous thrombosis, in order to 
make it possible to follow the changes in quality of life over time. Preferably a disease-
specific quality of life measure, such as the VT-QOL, is used to assess quality of life in 
future studies because disease-specific measures are more sensitive to specific problems 
patients with venous thrombosis are experiencing. It would also be interesting to assess 
whether illness perceptions predict other outcomes, such as biomedical variables such as 
persisting symptoms after 3 months, or return to work. Further research on illness per-
ceptions on quality of life in patients with venous thrombosis should also incorporate a 
measure of coping. It is likely that patients with venous thrombosis have developed dif-
ferent coping styles to deal with their illness, which were not assessed in the studies de-
scribed in this thesis. Although previous research has failed to confirm the premise of the 
Common-Sense Model that the relationship between illness perceptions and outcome is 
mediated through coping procedures, formal longitudinal research is still needed to prove 
the rejection of this premise. 
  In addition, an intervention study, like that of Petrie and colleagues (65) could be 
conducted to investigate the impact of a short intervention focused on changing illness 
perceptions on the well-being of patients with venous thrombosis. Such an intervention 
should focus primarily on beliefs in the duration of the disease, as well as on beliefs 
about the controllability and curability of venous thrombosis, since these are the illness 
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perceptions that seem to have the greatest influence on quality of life in patients with ve-
nous thrombosis. 
  Regarding the psychological consequences of genetic testing for thrombophilia, 
future research should focus more on the short-term effects of testing, since the studies 
described in this thesis only focussed on the long-term effects. Such a study should in-
vestigate a diverse group of thrombophilia patients with variation in risk factors. Ideally, 
it would have a randomized longitudinal design, with measurements of psychological dis-
tress immediately after receiving the test result and at a specified later time point, to in-
vestigate whether the duration and intensity of the perceived emotional impact of the test 
changes over time. In addition, it would be useful to include measures about state anxiety 
and depression following the genetic test result. This research could also help to clarify 
the exact nature of the predictive value of the Common-Sense Model in explaining out-
come in individuals at risk of a disease.    
Our study showed that there are a number of methodological problems that arise 
when attempting to capture illness perceptions of individuals ‘at risk’ of a certain disease 
with the original version of the IPQ-R. Further research should aim at refining the sub-
scales so that they adequately capture illness perceptions in this specific population. The 
development of a new version of the IPQ-R, specifically for patients ‘at risk’, could be a 
possible outcome. In addition, the Common-Sense Model needs to be expanded to en-
compass beliefs regarding control over risk when applied to individuals at risk of disease. 
Perceptions of personal control over prevention of the target disease, as well as beliefs 
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Venous thrombosis is the result of the formation of a blood clot in a vein. The most 
common manifestation is in the veins of the legs, but in can also occur in other body 
parts. The clot blocks the flow of blood in the affected body part, which can cause pain, 
swelling, redness, and tenderness of the skin. In some cases a piece of the clot breaks off 
and travels to the lungs, where it can cause a (possibly fatal) pulmonary embolism. Up to 
50% of all patients with venous thrombosis develop chronic problems. This is called the 
postthrombotic syndrome. Venous thrombosis has an annual incidence of 1-2 in 1000 
persons. 
 Venous thrombosis is a multicausal disease, caused by both genetic and environ-
mental risk factors. Environmental risk factors for venous thrombosis include the use of 
oral contraceptives (‘the Pill’), obesity, surgery, and prolonged immobility, for instance 
during a long flight. Genetic risk factors are inherited abnormalities affecting blood co-
agulation (thrombophilia), such as factor V Leiden and protein C deficiency. Individuals 
with inherited thrombophilia have a 16 times increased risk of venous thrombosis com-
pared with a normal population. A genetic test can be performed to detect thrombo-
philia. 
 Quality of life in relation to health is the subjective effect of illness and its conse-
quent therapy upon a patient. Quality of life is increasingly seen as an important outcome 
measure in scientific research. The impact of venous thrombosis on quality of life has not 
gained much attention in the scientific literature. This is remarkable, because venous 
thrombosis is a potentially fatal illness that often has chronic consequences. Therefore, 
venous thrombosis will probably have a large impact on the quality of life of patients.  
 Research has indicated that an increased risk of disease, such as thrombophilia, 
may influence daily life. Knowing that one has an increased risk of a disease, may in-
crease disease worry. This justifies research about the psychological impact of genetic 
testing for thrombophilia. The psychological consequences of genetic testing for throm-
bophilia have only received limited attention in the scientific literature. 
Research has shown that quality of life in chronic patients can not be explained by mere 
biomedical variables. In explaining health outcomes, such as quality of life, Leventhal’s 
Common-Sense Model (CSM) can be a useful model. The model describes how a patient 
processes information about his illness through a cognitive and emotional pathway, and 
develops illness perceptions. Furthermore, the model describes how these illness percep-
tions can influence health outcomes, such as quality of life. Illness perceptions include 
five components: the symptoms that patients associate with their illness (identity), their 
beliefs about the etiology (cause), the outcome (consequences), the duration (timeline) 
and the controllability (cure/control) of the illness. Earlier research found that illness 
perceptions play an important role in explaining quality of life in chronic patients. One of 
the premises of the Common-Sense Model is that illness perceptions are derived not only 
from direct somatic or symptomatic experience but also from information available in 




Therefore it is likely that the Common-Sense Model will prove to be a useful model in 
explaining outcome in individuals who are at risk of a certain illness. 
 Since 1985 a large North-American family (n~800) with protein C deficiency has 
been the subject of many studies (IPCI: International Protein C Investigation). A family 
of this size is ideal to study the psychological aspects of genetic testing for thrombo-
philia. Collaboration between the Department of Clinical Epidemiology (LUMC), the 
Unit of Psychology (LUMC) and the Department of Pathology of the University of 
Vermont (VT, USA) was established. This collaboration resulted in several studies on 
quality of life in patients with venous thrombosis and the psychological impact of 
thrombophilia testing, of which the results are described in this thesis.  
 
The studies described in this thesis had two main aims:  
1) To study the quality of life of patients with venous thrombosis and to examine the role 
of illness perceptions in explaining the quality of life of these patients.  
2) To assess the psychological consequences of genetic testing for thrombophilia, using 
the Common-Sense Model as a theoretical framework. 
 
The first aim of this thesis was addressed in chapters 2, 3, and 4. Chapter 2 describes a 
literature review that discusses all papers about quality of life in patients with venous 
thrombosis and other venous diseases that were published between 1996 and 2003. A 
total of 25 papers were identified, of which only 4 specifically dealt with the assessment 
of quality of life in patients with venous thrombosis. Main results of these studies indi-
cate that patients with venous thrombosis are impaired in their physical, social, and psy-
chological functioning, and that this impairment is related to the severity of the post-
thrombotic syndrome. Other studies dealt with quality of life assessment in patients with 
other venous diseases, such as chronic venous insufficiency, venous leg ulceration, and 
varicose veins. The remaining articles examined the effect of different types of treatment 
for venous thrombosis on quality of life. 
  Chapter 3 describes the results of a study in which quality of life in 45 patients 
with venous thrombosis was assessed. Quality of life was assessed with a generic meas-
ure, the SF-36, and a newly developed disease-specific measure, the VT-QOL.  The VT-
QOL was developed specifically for use in this patient population. Most patients in this 
study had their last thrombotic event some years ago. The results of this study indicated 
that the patients were still impaired in their daily functioning. They also experienced so-
cial and psychological impairment as a result of their venous thrombosis. Quality of life 
was related to self-reported symptoms and the presence of the postthrombotic syn-
drome. Furthermore, the VT-QOL appeared to be more sensitive to the specific prob-
lems patients with venous thrombosis are facing, than the SF-36. 
Chapter 4 describes the illness perceptions of the same group of 45 patients and assesses 




assessed using the Illness Perception Questionnaire-Revised (IPQ-R) and quality of life 
was assessed with the SF-36. Patients in this study believed that their illness would be 
prolonged and that their symptoms were not cyclical. They mostly attributed their venous 
thrombosis to bad luck or hereditary factors. The illness perceptions ‘timeline’ (the belief 
that the illness will have a long duration), ‘personal control’ (the belief in less personal 
control over the illness), ‘identity’ (the attribution of more symptoms to the illness) and 
the cause ‘heredity’ were the best predictors of quality of life scores. 
  Results of the studies described above show that the effect of venous thrombosis 
on quality of life should not be underestimated, even some years after the venous throm-
bosis. Furthermore, results give an indication that besides the presence of the post-
thrombotic syndrome, illness perceptions may help to explain quality of life in patients 
with venous thrombosis. 
 
Chapters 5 and 6, which together form part 2 of this thesis, address the second aim of 
this thesis. The study described in chapter 5 explored the attitudes toward genetic testing 
for heritable thrombophilia in the family with a high incidence of protein C deficiency 
described above. The questionnaire used in this study consisted of items about the beliefs 
in the psychological and health benefits of testing, beliefs in psychological distress after 
testing, risk perception, and thrombosis worry. Furthermore, knowledge about other risk 
factors for venous thrombosis, dispositional anxiety, and interest in getting a genetic test 
in non-tested individuals were assessed. Three groups of participants filled out the ques-
tionnaires. The total sample consisted of 168 family members of whom 76 had not been 
tested for protein C deficiency before. 92 participants had been tested previously, of 
whom 34 participants had protein C deficiency, and 58 participants did not have protein 
C deficiency. None of the participants had ever experienced venous thrombosis. The 
main conclusion of this study is that the psychological and health benefits of testing are 
perceived as higher than the psychological distress following the test. Perceived risk for 
venous thrombosis was not associated with any of the attitudes towards the test or with 
interest in getting a genetic test. Worry about venous thrombosis and dispositional anxi-
ety were related to psychological distress following the test result and in interest in get-
ting tested. This indicates that certain vulnerable individuals (with higher levels of dispo-
sitional anxiety) experience more negative consequences of receiving a positive test result 
for thrombophilia. 
  In chapter 6 the Common-Sense Model was applied to predict risk perception 
and worry in individuals with a genetic predisposition to venous thrombosis. A total of 
174 participants with thrombophilia completed a questionnaire, consisting of the IPQ-R 
and items about risk perception and thrombosis worry. 55% of the participants had suf-
fered from venous thrombosis. Results of this study show that individuals with and 
without a history of venous thrombosis had similar perceptions of the disease. Young age 




venous thrombosis. Illness perceptions had only limited influence on risk perception. 
Thrombosis worry could be better explained by illness perceptions than risk perception. 
Perceptions about the symptoms related to venous thrombosis (identity) and the conse-
quences of venous thrombosis (consequences) were the strongest predictors of thrombo-
sis worry. These results support the premise of the Common-Sense Model - that illness 
perceptions are derived not only from direct somatic or symptomatic experience but also 
from information available in the external social environment. 
  This part of the thesis shows that genetic testing for thrombophilia does not have 
many adverse psychological consequences. However, certain vulnerable individuals may 
still experience considerable worry about getting venous thrombosis. Furthermore, re-
sults indicate that the Common-Sense Model can act as a useful framework to enhance 
understanding of how factors contribute to influence psychological response to risk of 
disease. 
 
In chapter 7, the main results of the studies in this thesis are summarized and discussed. 
















Veneuze trombose is een ziekte die ontstaat door de vorming van een bloedstolsel in een 
ader. Veneuze trombose komt meestal voor in de benen, maar kan ook in andere li-
chaamsdelen voorkomen. Het stolsel blokkeert de bloedtoevoer in het betreffende li-
chaamsdeel, waardoor het lichaamsdeel pijn doet, gevoelig is, en er rood en gezwollen uit 
ziet. In sommige gevallen breekt een stukje van het stolsel af, en komt het vast te zitten 
in de longen, waar het een (mogelijk fatale) longembolie veroorzaakt. Tot 50% van alle 
patiënten met veneuze trombose blijft chronische klachten houden. Dit wordt het post-
trombotisch syndroom genoemd. Veneuze trombose komt jaarlijks bij 1-2 op de 1000 
mensen voor. 
 Veneuze trombose kan door verworven en genetische risicofactoren worden ver-
oorzaakt. Verworven risicofactoren voor veneuze trombose zijn onder andere het ge-
bruik van orale anticonceptie (‘de pil’), overgewicht, chirurgie, en langdurig stilzitten, bij-
voorbeeld tijdens een lange vlucht. Genetische risicofactoren zijn aangeboren afwijkingen 
in de bloedstolling (stollingsafwijkingen), zoals factor V Leiden en proteïne C deficiëntie. 
Mensen met een stollingsafwijking hebben een 16 maal verhoogd risico op veneuze 
trombose ten opzichte van de normale bevolking. Een genetische test kan worden uitge-
voerd om een stollingsafwijking vast te stellen. 
 Kwaliteit van leven in relatie tot gezondheid is het subjectieve effect van een ziek-
te en de behandeling op de patiënt. Kwaliteit van leven is een belangrijke uitkomstmaat 
in veel wetenschappelijk onderzoek. De invloed van veneuze trombose op het leven van 
de patiënt is weinig onderzocht. Dit is opmerkelijk, aangezien veneuze trombose een po-
tentieel dodelijke ziekte is die vaak chronische consequenties met zich meebrengt. Ve-
neuze trombose zal daarom waarschijnlijk een grote invloed hebben op de kwaliteit van 
leven van de patiënt.  
 Uit onderzoek is gebleken dat een verhoogd risico op een ziekte, zoals bij een 
stollingsafwijking het geval is, van invloed kan zijn op het dagelijkse leven. Kennis van 
een verhoogd ziekterisico kan bezorgdheid over het krijgen van de ziekte veroorzaken. 
Dit rechtvaardigt onderzoek naar de psychologische invloed van het testen van stollings-
afwijkingen. De psychologische gevolgen van het testen op stollingsafwijkingen hebben 
echter tot op heden in de wetenschappelijke literatuur nauwelijks aandacht gekregen.  
  Onderzoek heeft uitgewezen dat kwaliteit van leven bij chronisch zieke patiënten 
niet alleen door medische variabelen kan worden verklaard. Bij het verklaren van ziekte-
uitkomsten, zoals kwaliteit van leven, kan Leventhal’s ‘Common-Sense Model’ (CSM) 
een bruikbaar model zijn. Het model beschrijft hoe een patiënt via cognitieve en emotio-
nele mechanismen informatie over zijn ziekte verwerkt en ziektepercepties ontwikkelt. 
Vervolgens geeft het model aan hoe deze ziektepercepties klinische uitkomsten, zoals 
kwaliteit van leven, beïnvloeden. De ziektepercepties bestaan uit 5 componenten: percep-
ties over de klachten die bij de ziekte horen (identiteit), de duur van de ziekte (tijdsduur), 
de gevolgen van de ziekte (consequenties), de oorzaken van de ziekte (oorzaken) en de 




derzoek wijst uit dat kwaliteit van leven van chronisch zieke patiënten in hoge mate 
wordt bepaald door hun ziektepercepties. Een van de vooronderstellingen van het 
Common-Sense Model is dat ziektepercepties niet alleen door directe of symptomatische 
ervaringen worden gevormd, maar ook door informatie uit de sociale omgeving. Het is 
daarom waarschijnlijk dat het Common-Sense Model ook een nuttig model zal zijn voor 
het verklaren van uitkomsten bij patiënten met een verhoogd risico op een ziekte. 
 Sinds 1985 is een grote Noord-Amerikaanse familie (n~800) met proteïne C defi-
ciëntie het onderwerp van diverse studies geweest (IPCI: International Protein C Investi-
gation). Zo’n familie is een ideale onderzoekspopulatie om de psychologische gevolgen 
van het testen op stollingsafwijkingen te bestuderen. Een samenwerking tussen de afde-
lingen Medische Psychologie en Klinische Epidemiologie, LUMC, en de Universiteit van 
Vermont (VT, USA) werd aangegaan. Dit heeft geresulteerd in diverse studies naar de 
kwaliteit van leven van patiënten met veneuze trombose, en de psychologische gevolgen 
van het testen op stollingsafwijkingen. De resultaten van deze studies staan in dit proef-
schrift beschreven. 
 
De studies in dit proefschrift hadden twee doelen: 
1. Het bestuderen van de kwaliteit van leven van patiënten met veneuze trombose. Hier-
bij wordt de rol van ziektepercepties in de verklaring van de kwaliteit van leven van deze 
patiënten meegenomen. 
2. Het bestuderen van de psychologische invloed van het testen op stollingsafwijkingen, 
waarbij het Common-Sense Model als theoretisch kader wordt gebruikt. 
 
Deel 1 van het proefschrift, hoofdstukken 2, 3, en 4, behandelt het eerste doel. Hoofd-
stuk 2 beschrijft een literatuuronderzoek waarin alle artikelen worden besproken die tus-
sen 1996 en 2003 over kwaliteit van leven bij patiënten met veneuze trombose en andere 
veneuze ziekten zijn gepubliceerd. Vijfentwintig artikelen werden gevonden, waarvan 
slechts vier artikelen specifiek onderzoek over de kwaliteit van leven van patiënten met 
veneuze trombose bespraken. Deze studies vonden dat patiënten met veneuze trombose 
zowel in hun fysiek, sociaal, als mentaal functioneren beperkt zijn, en dat deze beperking 
samenhangt met de ernst van het posttrombotisch syndroom. Andere artikelen behan-
delden studies over kwaliteit van leven van patiënten met andere veneuze ziekten, zoals 
spataderen, open wonden en flebitis. De overige artikelen bespraken de invloed van ver-
schillende behandelvormen voor veneuze trombose op kwaliteit van leven.  
 In hoofdstuk 3 worden de resultaten van een onderzoek beschreven waarin de 
kwaliteit van leven van 45 patiënten met veneuze trombose met een generieke vragenlijst 
(de SF-36), en een ziekte-specifieke vragenlijst (VT-QOL) werd gemeten. De VT-QOL 
werd speciaal voor deze groep patiënten ontwikkeld. De laatste keer dat de patiënten ve-
neuze trombose hadden was in veel gevallen al enige jaren geleden. De resultaten van 




dagelijks functioneren. Zij ondervonden ook sociale en psychologische nadelen van de 
doorgemaakte trombose. Vooral patiënten met het posttrombotisch syndroom, en pa- 
tiënten die zelf aangaven nog steeds veel lichamelijke klachten te hebben, hadden een 
lagere kwaliteit van leven vergeleken met populatienormen. Tevens bleek de VT-QOL 
beter geschikt dan de SF-36 om de specifieke problemen waar trombosepatiënten mee te 
maken hebben te detecteren. 
 Hoofdstuk 4 beschrijft de ziektepercepties van dezelfde groep van 45 patiënten 
en kijkt hoe deze percepties samenhangen met de kwaliteit van leven van de patiënten. 
Ziektepercepties werden met de Illness Perception Questionnaire-Revised (IPQ-R) ge-
meten, en kwaliteit van leven werd door middel van de SF-36 bepaald. Patiënten in dit 
onderzoek geloofden dat hun ziekte lang zou duren en geloofden niet dat de symptomen 
van hun ziekte cyclisch waren. De oorzaak van hun ziekte schreven zij vooral aan pech 
en genetische factoren toe. De ziektepercepties ‘tijdslijn’ (het idee dat de ziekte langer zal 
duren), ‘beheersing’ (het ervaren van minder controle over de ziekte), ‘identiteit’ (het toe-
schrijven van meer symptomen aan de ziekte) en ‘genetische oorzaak’ (het toeschrijven 
van de ziekte aan genetische factoren) hingen samen met een slechtere kwaliteit van le-
ven.  
 Bovenstaand beschreven onderzoeken laten zien dat het effect van veneuze 
trombose op de kwaliteit van leven van patiënten met veneuze trombose ook enige jaren 
na het doormaken van de trombose niet onderschat moet worden. Verder blijkt dat naast 
het posttrombotisch syndroom ook ziektepercepties de kwaliteit van leven van patiënten 
met veneuze trombose bepalen. 
 
Hoofdstukken 5 en 6, die samen deel 2 van dit proefschrift vormen, gaan in op het twee-
de doel van dit proefschrift. De studie beschreven in hoofdstuk 5 onderzocht de attitu-
des ten opzichte van genetisch testen voor stollingsafwijkingen in de eerder beschreven 
familie met een hoge incidentie van proteïne C deficiëntie. De daarbij gebruikte vragen-
lijst bestond uit vragen over gezondheids- en psychologisch voordeel van testen, psycho-
logisch lijden na het testen, en vragen over risicoperceptie en bezorgdheid over het krij-
gen van trombose. Verder werden de kennis over de oorzaken van veneuze trombose, de 
interesse van niet-geteste familieleden in het krijgen van een test, en de dispositionele 
angst van de deelnemers bepaald. Drie groepen familieleden vulden de vragenlijsten in. 
De totale onderzoekspopulatie bestond uit 168 familieleden. 76 deelnemers waren niet 
eerder getest op proteïne C deficiëntie. 92 deelnemers waren wel getest, waarvan 34 posi-
tief en 58 negatief waren voor proteïne C deficiëntie. Geen van de deelnemers had ooit 
veneuze trombose gehad. De belangrijkste conclusie van dit onderzoek is dat de deelne-
mers de gezondheids- en psychologische voordelen van het genetisch testen zwaarder 
lieten wegen dan de nadelen (psychologisch leed). Risicoperceptie bleek niet gerelateerd 
te zijn aan attitudes ten opzichte van de test of aan interesse in het ondergaan van een 




relateren aan psychologisch leed en aan de interesse om getest te worden. Dit geeft aan 
dat individuen met een bepaalde kwetsbaarheid (zoals dispositionele angst) meer nadelen 
van genetisch testen voor stollingsafwijkingen ondervinden. 
 In hoofdstuk 6 wordt het Common-Sense Model toegepast om risicoperceptie en 
bezorgdheid over trombose bij mensen met een stollingsafwijking te verklaren. Een 
groep van 174 deelnemers met een stollingsafwijking vulde een vragenlijst in, bestaande 
uit de IPQ-R, en aangevuld met vragen over risicoperceptie en bezorgdheid. Van alle 
deelnemers had 55% trombose gehad. De resultaten van dit onderzoek laten zien dat de 
ziektepercepties van de deelnemers met of zonder een trombosegeschiedenis niet van 
elkaar verschilden. Verder bleken vooral een lagere leeftijd en een trombosegeschiedenis 
van invloed te zijn op risicoperceptie. Ziektepercepties droegen weinig bij aan het verkla-
ren van risicoperceptie. Bezorgdheid over het krijgen van trombose was beter te verkla-
ren door ziektepercepties dan risicoperceptie. De percepties over de klachten bij trombo-
se (identiteit) en over de gevolgen van trombose (consequenties) waren de sterkste voor-
spellers. Deze resultaten ondersteunen de vooronderstelling van het Common-Sense 
Model, dat ziektepercepties niet alleen ontstaan via persoonlijke ervaring met de ziekte, 
maar ook via informatie uit de omgeving, zoals bij het hebben van een genetisch ver-
hoogd risico het geval is. 
 Dit deel van het proefschrift laat zien dat het testen op stollingafwijkingen weinig 
negatieve gevolgen heeft. Desondanks kunnen bepaalde kwetsbare individuen veel be-
zorgdheid over het krijgen van trombose ervaren. Verder bleek het Common-Sense Mo-
del nuttig bij het verkrijgen van inzicht op de verschillende factoren die de psychologi-
sche invloed van een verhoogd ziekterisico beïnvloeden. 
   
In hoofdstuk 7 worden de belangrijkste resultaten van de studies uit dit proefschrift sa- 
mengevat en bediscussieerd. Ook worden in dit hoofdstuk aanbevelingen voor de klin-













Eindelijk is het dan zover: het proefschrift is voltooid. Ik heb een geweldige promotietijd 
gehad en op deze plaats wil ik de mensen bedanken zonder wie mijn promotietijd de af-
gelopen jaren een stuk minder aangenaam en succesvol was geweest. 
Allereerst mijn collega’s van de afdeling Medische Psychologie, en het laatste jaar ook de 
collega’s van Klinische- en Gezondheidspsychologie, bedankt voor de gezelligheid en 
steun. 
Thanks to all my colleagues from Vermont for the opportunity to visit your beautiful 
State and for all the hospitality during my stay. 
Lucia Snoei, dankzij jouw creativiteit heb ik nu een schitterende cover. Bedankt! 
Kamergenote Geeske ten Wolde en ex-kamergenote Desiree Helder: heel erg bedankt 
voor het opfleuren van mijn werkdagen.  
Mijn twee paranimfen; Carla Vossen en Jannelien Wieland. Carla, vorig jaar stond ik 
naast jou, en nu zal jij naast mij staan. Bedankt voor de fijne samenwerking en de gezelli-
ge lunches bij Lebkov. Jannelien, je bent een geweldige vriendin en ik weet zeker dat je 
ook een geweldige paranimf zult zijn. 
Een speciale dank aan mijn vrienden en vriendinnen en aan mijn zusje Cornalijne: be-
dankt voor alle afleiding en plezier in de vorm van vakanties, etentjes, avondjes uit, mail-
tjes, en telefoongesprekken.  
In deze categorie wil ik graag mijn ‘oudste’ vriendinnen Iris en Ardien nog speciaal noe-
men; ik vind onze inmiddels 15 jaar oude vriendschap heel erg waardevol! 
Lieve Wessel, hier is hij dan, de lang geleden beloofde disclaimer: dankzij (of ondanks?) 
jou heeft dit proefschrift geen enkele vertraging opgelopen!  
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